primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
139993012,13999301,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2018,Q1,Hypocalcaemia,,2018,Q1,2,F,,20171215.0,20170922,20180320,PER,US-MLMSERVICE-20170712-0805054-1,US-LUPIN PHARMACEUTICALS INC.-2017-04018,LUPIN,,68.0,YR,,F,Y,,,20180320.0,,OT,US,US,2018,Q1,Elderly
139993012,13999301,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2018,Q1,Hypomagnesaemia,,2018,Q1,2,F,,20171215.0,20170922,20180320,PER,US-MLMSERVICE-20170712-0805054-1,US-LUPIN PHARMACEUTICALS INC.-2017-04018,LUPIN,,68.0,YR,,F,Y,,,20180320.0,,OT,US,US,2018,Q1,Elderly
141305503,14130550,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q1,Underdose,,2018,Q1,3,F,20170725.0,20170726.0,20171026,20180125,PER,,US-AMGEN-USASL2017114543,AMGEN,,63.0,YR,A,F,Y,,,20180125.0,,MD,US,US,2018,Q1,Adult
141549563,14154956,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QW",,,U,U,,,,1.5,MG,,/wk,2018,Q1,Acute kidney injury,,2018,Q1,3,F,20170919.0,20180119.0,20171102,20180124,EXP,,PHHO2017US015008,NOVARTIS,,61.0,YR,,M,Y,,,20180124.0,,MD,US,US,2018,Q1,Adult
141549563,14154956,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QW",,,U,U,,,,1.5,MG,,/wk,2018,Q1,Respiratory failure,,2018,Q1,3,F,20170919.0,20180119.0,20171102,20180124,EXP,,PHHO2017US015008,NOVARTIS,,61.0,YR,,M,Y,,,20180124.0,,MD,US,US,2018,Q1,Adult
141549563,14154956,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QW",,,U,U,,,,1.5,MG,,/wk,2018,Q1,Urinary retention,,2018,Q1,3,F,20170919.0,20180119.0,20171102,20180124,EXP,,PHHO2017US015008,NOVARTIS,,61.0,YR,,M,Y,,,20180124.0,,MD,US,US,2018,Q1,Adult
142091082,14209108,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q1,Diverticulum intestinal haemorrhagic,,2018,Q1,2,F,20170616.0,20171211.0,20171121,20180117,PER,,US-JNJFOC-20171015196,JANSSEN,,77.0,YR,E,M,Y,,,20180117.0,,CN,US,US,2018,Q1,Elderly
142155672,14215567,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Other,,,,D,,,,,1.5,MG,SOLUTION FOR INJECTION,/wk,2018,Q1,Blood testosterone increased,,2018,Q1,2,F,20170529.0,20171220.0,20171122,20180117,PER,,US-JNJFOC-20171105068,JANSSEN,,67.0,YR,E,M,Y,108.2,KG,20180117.0,,MD,US,US,2018,Q1,Elderly
142457164,14245716,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QWK",,,,,,,,0.75,MG,,/wk,2018,Q1,Myocardial ischaemia,,2018,Q1,4,F,20171115.0,20180109.0,20171204,20180111,EXP,,JP-AMGEN-JPNCT2017177624,AMGEN,,76.0,YR,E,F,Y,,,20180111.0,,OT,JP,JP,2018,Q1,Elderly
143434642,14343464,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,UNKNOWN,,2018,Q1,Muscular weakness,,2018,Q1,2,F,20171211.0,20171229.0,20180102,20180105,EXP,,US-CELGENEUS-USA-20171209857,CELGENE,,51.0,YR,,F,Y,90.07,KG,20180105.0,,MD,US,US,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Acidosis,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Altered state of consciousness,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Blood pH abnormal,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Dehydration,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Diarrhoea,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Gastrointestinal oedema,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Hyperlipidaemia,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Intestinal haemorrhage,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Metabolic acidosis,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143614233,14361423,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,INJECTION,,2018,Q1,Renal failure,,2018,Q1,3,F,201707.0,20180109.0,20180108,20180110,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-000305",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,130.0,KG,20180110.0,,PH,DE,DE,2018,Q1,Adult
143817522,14381752,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q1,Maternal exposure during pregnancy,,2018,Q1,2,F,20171129.0,20180122.0,20180112,20180125,PER,,US-GILEAD-2018-0315597,GILEAD,,37.0,YR,A,F,Y,90.3,KG,20180125.0,,OT,US,US,2018,Q1,Adult
144111842,14411184,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNSPECIFIED,,2018,Q1,Acute kidney injury,,2018,Q1,2,F,20160728.0,20180220.0,20180119,20180223,EXP,,US-JNJFOC-20171224039,JANSSEN,,38.0,YR,A,F,Y,124.29,KG,20180223.0,,CN,US,US,2018,Q1,Adult
144111842,14411184,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNSPECIFIED,,2018,Q1,Sepsis,,2018,Q1,2,F,20160728.0,20180220.0,20180119,20180223,EXP,,US-JNJFOC-20171224039,JANSSEN,,38.0,YR,A,F,Y,124.29,KG,20180223.0,,CN,US,US,2018,Q1,Adult
144111842,14411184,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNSPECIFIED,,2018,Q1,Urinary tract infection,,2018,Q1,2,F,20160728.0,20180220.0,20180119,20180223,EXP,,US-JNJFOC-20171224039,JANSSEN,,38.0,YR,A,F,Y,124.29,KG,20180223.0,,CN,US,US,2018,Q1,Adult
144180281,14418028,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,UNK,,,,,,,,,,,,2018,Q1,Heart rate increased,,2018,Q1,1,I,20180116.0,20180117.0,20180122,20180122,EXP,,US-TAKEDA-2018TUS001541,TAKEDA,,57.0,YR,,M,Y,68.03,KG,20180122.0,,MD,US,US,2018,Q1,Adult
144180281,14418028,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,UNK,,,,,,,,,,,,2018,Q1,Impulsive behaviour,,2018,Q1,1,I,20180116.0,20180117.0,20180122,20180122,EXP,,US-TAKEDA-2018TUS001541,TAKEDA,,57.0,YR,,M,Y,68.03,KG,20180122.0,,MD,US,US,2018,Q1,Adult
144180281,14418028,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,UNK,,,,,,,,,,,,2018,Q1,Memory impairment,,2018,Q1,1,I,20180116.0,20180117.0,20180122,20180122,EXP,,US-TAKEDA-2018TUS001541,TAKEDA,,57.0,YR,,M,Y,68.03,KG,20180122.0,,MD,US,US,2018,Q1,Adult
144180281,14418028,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,UNK,,,,,,,,,,,,2018,Q1,Suicidal ideation,,2018,Q1,1,I,20180116.0,20180117.0,20180122,20180122,EXP,,US-TAKEDA-2018TUS001541,TAKEDA,,57.0,YR,,M,Y,68.03,KG,20180122.0,,MD,US,US,2018,Q1,Adult
144188981,14418898,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,"1.5 MG, UNK",,,U,,,,,1.5,MG,INJECTION,,2018,Q1,Diarrhoea,,2018,Q1,1,I,20170820.0,20180108.0,20180122,20180122,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-005057,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,,,20180122.0,,MD,IT,IT,2018,Q1,Adult
144188981,14418898,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,"1.5 MG, UNK",,,U,,,,,1.5,MG,INJECTION,,2018,Q1,Rectal haemorrhage,,2018,Q1,1,I,20170820.0,20180108.0,20180122,20180122,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-005057,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,,,20180122.0,,MD,IT,IT,2018,Q1,Adult
144188981,14418898,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,"1.5 MG, UNK",,,U,,,,,1.5,MG,INJECTION,,2018,Q1,Weight decreased,,2018,Q1,1,I,20170820.0,20180108.0,20180122,20180122,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-005057,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,,,20180122.0,,MD,IT,IT,2018,Q1,Adult
144232171,14423217,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNKNOWN,,2018,Q1,Chest discomfort,,2018,Q1,1,I,2017.0,20180109.0,20180123,20180123,PER,,US-JNJFOC-20180109974,JANSSEN,,38.0,YR,A,F,Y,130.64,KG,20180123.0,,OT,US,US,2018,Q1,Adult
144232171,14423217,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNKNOWN,,2018,Q1,Dyspnoea,,2018,Q1,1,I,2017.0,20180109.0,20180123,20180123,PER,,US-JNJFOC-20180109974,JANSSEN,,38.0,YR,A,F,Y,130.64,KG,20180123.0,,OT,US,US,2018,Q1,Adult
144232171,14423217,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNKNOWN,,2018,Q1,Hypersensitivity,,2018,Q1,1,I,2017.0,20180109.0,20180123,20180123,PER,,US-JNJFOC-20180109974,JANSSEN,,38.0,YR,A,F,Y,130.64,KG,20180123.0,,OT,US,US,2018,Q1,Adult
144232171,14423217,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNKNOWN,,2018,Q1,Infusion related reaction,,2018,Q1,1,I,2017.0,20180109.0,20180123,20180123,PER,,US-JNJFOC-20180109974,JANSSEN,,38.0,YR,A,F,Y,130.64,KG,20180123.0,,OT,US,US,2018,Q1,Adult
144232171,14423217,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNKNOWN,,2018,Q1,Psoriasis,,2018,Q1,1,I,2017.0,20180109.0,20180123,20180123,PER,,US-JNJFOC-20180109974,JANSSEN,,38.0,YR,A,F,Y,130.64,KG,20180123.0,,OT,US,US,2018,Q1,Adult
144257561,14425756,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,20180120.0,,20180122,20180122,DIR,,,FDA-CTU,,56.0,YR,,F,N,93.0,KG,20180122.0,N,PH,US,US,2018,Q1,Adult
144726252,14472625,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2018,Q1,Acute coronary syndrome,,2018,Q1,2,F,,20180131.0,20180201,20180214,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-008421,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,89.0,KG,20180214.0,,PH,JP,JP,2018,Q1,Adult
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Asthenia,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Blood thyroid stimulating hormone normal,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Dyspepsia,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Feeling jittery,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Feeling of body temperature change,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Gastrointestinal motility disorder,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Glycosylated haemoglobin increased,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Headache,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Herpes zoster,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Joint swelling,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Night sweats,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Pain,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Pruritus,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
144840521,14484052,3,C,TRULICITY(DULAGLUTIDE),,2,,,,,D,,,,,1.5,MG,,,2018,Q1,Weight increased,,2018,Q1,1,I,201705.0,20180124.0,20180205,20180205,EXP,,FR-MERCK KGAA-2041363,MERCK KGAA,,66.0,YR,,F,Y,85.0,KG,20180205.0,,,COUNTRY NOT SPECIFIED,FR,2018,Q1,Elderly
145177201,14517720,27,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q1,Obstructive pancreatitis,,2018,Q1,1,I,20170331.0,,20180209,20180209,DIR,,,FDA-CTU,,63.0,YR,,M,N,102.2,KG,20180209.0,Y,CN,US,US,2018,Q1,Adult
145234042,14523404,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,D,,,,,1.5,MG,INJECTION,/wk,2018,Q1,Asthenia,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,D,,,,,1.5,MG,INJECTION,/wk,2018,Q1,Blood glucose increased,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,D,,,,,1.5,MG,INJECTION,/wk,2018,Q1,Fatigue,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,D,,,,,1.5,MG,INJECTION,/wk,2018,Q1,Feeling abnormal,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,D,,,,,1.5,MG,INJECTION,/wk,2018,Q1,Glycosylated haemoglobin increased,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,D,,,,,1.5,MG,INJECTION,/wk,2018,Q1,Malaise,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,D,,,,,1.5,MG,INJECTION,/wk,2018,Q1,Thirst,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145287221,14528722,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2018,Q1,Hospitalisation,,2018,Q1,1,I,,20180207.0,20180214,20180214,EXP,,US-AMGEN-USASP2018018005,AMGEN,,58.0,YR,A,M,Y,,,20180214.0,,MD,US,US,2018,Q1,Adult
145287221,14528722,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2018,Q1,Wrong technique in product usage process,,2018,Q1,1,I,,20180207.0,20180214,20180214,EXP,,US-AMGEN-USASP2018018005,AMGEN,,58.0,YR,A,M,Y,,,20180214.0,,MD,US,US,2018,Q1,Adult
145323251,14532325,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q1,Obstructive pancreatitis,,2018,Q1,1,I,20170331.0,20180209.0,20180214,20180214,EXP,,US-009507513-1802USA005169,MERCK,,63.0,YR,,M,Y,102.2,KG,20180214.0,,CN,US,US,2018,Q1,Adult
145428951,14542895,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,20180121.0,20180206.0,20180216,20180216,EXP,,GB-JNJFOC-20180208238,JANSSEN,,57.0,YR,A,M,Y,64.1,KG,20180216.0,,MD,GB,GB,2018,Q1,Adult
145731031,14573103,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,D,D,,,,,,,,2018,Q1,Intestinal mass,,2018,Q1,1,I,20171213.0,,20180223,20180223,DIR,,,FDA-CTU,,46.0,YR,,F,N,78.75,KG,20180223.0,N,MD,US,US,2018,Q1,Adult
145731031,14573103,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,D,D,,,,,,,,2018,Q1,Pancreatic disorder,,2018,Q1,1,I,20171213.0,,20180223,20180223,DIR,,,FDA-CTU,,46.0,YR,,F,N,78.75,KG,20180223.0,N,MD,US,US,2018,Q1,Adult
145731031,14573103,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,D,D,,,,,,,,2018,Q1,Volvulus,,2018,Q1,1,I,20171213.0,,20180223,20180223,DIR,,,FDA-CTU,,46.0,YR,,F,N,78.75,KG,20180223.0,N,MD,US,US,2018,Q1,Adult
146411831,14641183,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"2 MG, QW",,,D,,,,,2.0,MG,,/wk,2018,Q1,Blood calcitonin increased,,2018,Q1,1,I,,20180301.0,20180315,20180315,EXP,,US-MYLANLABS-2018M1015567,MYLAN,,56.0,YR,,F,Y,,,20180315.0,,OT,US,US,2018,Q1,Adult
146470931,14647093,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,Y,,,,,,,UNSPECIFIED,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,20160124.0,20180312.0,20180316,20180316,EXP,,US-JNJFOC-20180319036,JANSSEN,,40.0,YR,A,F,Y,,,20180316.0,,CN,US,US,2018,Q1,Adult
146579531,14657953,1,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,Y,U,,,,2.0,MG,,/wk,2018,Q1,Blood calcitonin increased,,2018,Q1,1,I,,20180313.0,20180320,20180320,EXP,,US-DEXPHARM-20180185,DEXCEL,"SHERMAN, S. I.; KLOOS, R. T.; TUTTLE, R. M.; PONTECORVI, A.; VOLZKE, H.; HARPER, K.; VANCE, C.; ALSTON, J. T.; USBORNE, A. L.; SLOOP, K.W.; LAKSHMANAN, M.  NO CALCITONIN CHANGE IN A PERSON TAKING DULAGLUTIDE DIAGNOSED WITH PRE- EXISTING MEDULLARY THYROID CANCER.?          DIABETIC MEDICINE 2018, V35, P381-385  ?",56.0,YR,A,F,Y,,,20180320.0,,OT,US,US,2018,Q1,Adult
146598391,14659839,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,,, C850286,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE,,2018,Q1,Inappropriate schedule of drug administration,,2018,Q1,1,I,20180206.0,20180219.0,20180320,20180320,PER,,US-ELI_LILLY_AND_COMPANY-US201802008086,ELI LILLY AND CO,,53.0,YR,,F,Y,,,20180320.0,,CN,US,US,2018,Q1,Adult
146598391,14659839,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,,, C850286,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE,,2018,Q1,Incorrect dose administered,,2018,Q1,1,I,20180206.0,20180219.0,20180320,20180320,PER,,US-ELI_LILLY_AND_COMPANY-US201802008086,ELI LILLY AND CO,,53.0,YR,,F,Y,,,20180320.0,,CN,US,US,2018,Q1,Adult
146691711,14669171,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,2.0,MG,,/wk,2018,Q1,Blood calcitonin increased,,2018,Q1,1,I,,20180312.0,20180322,20180322,EXP,,US-TEVA-2018-US-872992,TEVA,"SHERMAN S, KLOOS R, TUTTLE R, PONTECORVI A, VOLZKE H, HARPER K.",56.0,YR,,F,Y,,,20180322.0,,OT,US,US,2018,Q1,Adult
146764361,14676436,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,N,D, C87949,201906,,1.5,MG,,QW,2018,Q1,Pancreatitis,,2018,Q1,1,I,20180313.0,,20180323,20180323,DIR,,,FDA-CTU,,72.0,YR,,M,N,,,20180323.0,N,PH,US,US,2018,Q1,Elderly
146787241,14678724,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,,2 MILLIGRAM,,,,,,,,2.0,MG,,,2018,Q1,Blood calcitonin increased,,2018,Q1,1,I,,20180312.0,20180326,20180326,EXP,,US-AUROBINDO-AUR-APL-2018-016171,AUROBINDO,,56.0,YR,,F,Y,,,20180326.0,,OT,US,US,2018,Q1,Adult
146787241,14678724,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,,2 MILLIGRAM,,,,,,,,2.0,MG,,,2018,Q1,Medullary thyroid cancer,,2018,Q1,1,I,,20180312.0,20180326,20180326,EXP,,US-AUROBINDO-AUR-APL-2018-016171,AUROBINDO,,56.0,YR,,F,Y,,,20180326.0,,OT,US,US,2018,Q1,Adult
146853861,14685386,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,,20180323.0,20180327,20180327,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-016547",BOEHRINGER INGELHEIM,"SHARMA P, JOBANPUTRA Y, LEWIN K, BAGATELL S, LICHTSTEIN D. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS - A CASE SERIES. REVIEWS ON RECENT CLINICAL TRIALS. 2018;13:1-5.",63.0,YR,,F,Y,,,20180327.0,,OT,US,US,2018,Q1,Adult
146853861,14685386,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2018,Q1,Enteritis,,2018,Q1,1,I,,20180323.0,20180327,20180327,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-016547",BOEHRINGER INGELHEIM,"SHARMA P, JOBANPUTRA Y, LEWIN K, BAGATELL S, LICHTSTEIN D. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS - A CASE SERIES. REVIEWS ON RECENT CLINICAL TRIALS. 2018;13:1-5.",63.0,YR,,F,Y,,,20180327.0,,OT,US,US,2018,Q1,Adult
146948421,14694842,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,125469.0,,,,,2018,Q1,Fatigue,,2018,Q1,1,I,20180308.0,20180320.0,20180329,20180329,EXP,GB-MHRA-TPP35695081C4205719YC1520507147350,GB-ELI_LILLY_AND_COMPANY-GB201803009120,ELI LILLY AND CO,,76.0,YR,,F,Y,88.0,KG,20180329.0,,CN,GB,GB,2018,Q1,Elderly
146948421,14694842,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,125469.0,,,,,2018,Q1,Influenza like illness,,2018,Q1,1,I,20180308.0,20180320.0,20180329,20180329,EXP,GB-MHRA-TPP35695081C4205719YC1520507147350,GB-ELI_LILLY_AND_COMPANY-GB201803009120,ELI LILLY AND CO,,76.0,YR,,F,Y,88.0,KG,20180329.0,,CN,GB,GB,2018,Q1,Elderly
1278732910,12787329,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,U,,,,,,,,2018,Q2,Bronchitis,,2018,Q2,10,F,20160831.0,20180618.0,20160927,20180628,EXP,,US-UCBSA-2016035654,UCB,,44.0,YR,,F,Y,,,20180628.0,,CN,US,US,2018,Q2,Adult
1278732910,12787329,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,U,,,,,,,,2018,Q2,Fatigue,,2018,Q2,10,F,20160831.0,20180618.0,20160927,20180628,EXP,,US-UCBSA-2016035654,UCB,,44.0,YR,,F,Y,,,20180628.0,,CN,US,US,2018,Q2,Adult
1278732910,12787329,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,U,,,,,,,,2018,Q2,Malaise,,2018,Q2,10,F,20160831.0,20180618.0,20160927,20180628,EXP,,US-UCBSA-2016035654,UCB,,44.0,YR,,F,Y,,,20180628.0,,CN,US,US,2018,Q2,Adult
1278732910,12787329,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,U,,,,,,,,2018,Q2,Pain,,2018,Q2,10,F,20160831.0,20180618.0,20160927,20180628,EXP,,US-UCBSA-2016035654,UCB,,44.0,YR,,F,Y,,,20180628.0,,CN,US,US,2018,Q2,Adult
1278732910,12787329,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,U,,,,,,,,2018,Q2,Psoriatic arthropathy,,2018,Q2,10,F,20160831.0,20180618.0,20160927,20180628,EXP,,US-UCBSA-2016035654,UCB,,44.0,YR,,F,Y,,,20180628.0,,CN,US,US,2018,Q2,Adult
1278732910,12787329,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,U,,,,,,,,2018,Q2,Rash,,2018,Q2,10,F,20160831.0,20180618.0,20160927,20180628,EXP,,US-UCBSA-2016035654,UCB,,44.0,YR,,F,Y,,,20180628.0,,CN,US,US,2018,Q2,Adult
141996013,14199601,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,,,,U,,,,,50.0,MG,,QD,2018,Q2,Cardiac failure,,2018,Q2,3,F,,20180524.0,20171117,20180528,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006662",BOEHRINGER INGELHEIM,"HARADA Y, IZAWA H, OKUNO G, UEDA Y, TAHARA Y, KANEKO S. FOUR CASES OF SIGNIFICANT SIDE EFFECTS ASSOCIATED WITH SGLT2 INHIBITORS.",70.0,YR,,M,Y,40.0,KG,20180528.0,,MD,JP,JP,2018,Q2,Elderly
141996013,14199601,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,,,,U,,,,,50.0,MG,,QD,2018,Q2,Thirst,,2018,Q2,3,F,,20180524.0,20171117,20180528,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006662",BOEHRINGER INGELHEIM,"HARADA Y, IZAWA H, OKUNO G, UEDA Y, TAHARA Y, KANEKO S. FOUR CASES OF SIGNIFICANT SIDE EFFECTS ASSOCIATED WITH SGLT2 INHIBITORS.",70.0,YR,,M,Y,40.0,KG,20180528.0,,MD,JP,JP,2018,Q2,Elderly
143320642,14332064,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,U,,,,,,,,2018,Q2,Drug interaction,,2018,Q2,2,F,20171017.0,20180210.0,20171228,20180424,EXP,,DE-AUROBINDO-AUR-APL-2017-47174,AUROBINDO,,0.0,DY,,M,Y,109.0,KG,20180424.0,,MD,DE,DE,2018,Q2,Child
143320642,14332064,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,U,,,,,,,,2018,Q2,Pulmonary embolism,,2018,Q2,2,F,20171017.0,20180210.0,20171228,20180424,EXP,,DE-AUROBINDO-AUR-APL-2017-47174,AUROBINDO,,0.0,DY,,M,Y,109.0,KG,20180424.0,,MD,DE,DE,2018,Q2,Child
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Abdominal pain upper,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Blood glucose abnormal,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Clostridium bacteraemia,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Diabetic ketoacidosis,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Diarrhoea,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Dyspnoea exertional,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Gastritis,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Hepatic enzyme abnormal,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Nausea,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Pain,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Pancreatic enzymes increased,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Peritonitis,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Pulmonary embolism,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Tachyarrhythmia,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Tachypnoea,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Thrombosis,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
144588092,14458809,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,,,125469.0,,,,/wk,2018,Q2,Vomiting,,2018,Q2,2,F,20171104.0,20180502.0,20180130,20180504,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201801007971,ELI LILLY AND CO,,48.0,YR,,F,Y,81.0,KG,20180504.0,,CN,DE,DE,2018,Q2,Adult
145991822,14599182,1,PS,Dulaglutide 0.75mg,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,INJECTION,/wk,2018,Q2,Constipation,,2018,Q2,2,F,20180117.0,20180411.0,20180305,20180417,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201802010269,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20180417.0,,CN,JP,JP,2018,Q2,Elderly
145991822,14599182,1,PS,Dulaglutide 0.75mg,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,INJECTION,/wk,2018,Q2,Urethritis,,2018,Q2,2,F,20180117.0,20180411.0,20180305,20180417,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201802010269,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20180417.0,,CN,JP,JP,2018,Q2,Elderly
146218303,14621830,3,SS,DULAGLUTIDE(GENETICAL RECOMBINATION),DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q2,Altered state of consciousness,,2018,Q2,3,F,201710.0,20180330.0,20180310,20180407,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001154",BOEHRINGER INGELHEIM,"TOHARA R, IMAIZUMI T, HORIYA Y, FUJISAWA T, SHIBATA T, TANABASHI S, ETAL. A CASE OF DIABETIC KETOACIDOSIS IN A PATIENT WITH POSITIVE ANTI-INSULIN ANTIBODY AND ANTI-INSULIN RECEPTOR ANTIBODY.",86.0,YR,,M,Y,,,20180407.0,,MD,JP,JP,2018,Q2,Elderly
146218303,14621830,3,SS,DULAGLUTIDE(GENETICAL RECOMBINATION),DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q2,Decreased appetite,,2018,Q2,3,F,201710.0,20180330.0,20180310,20180407,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001154",BOEHRINGER INGELHEIM,"TOHARA R, IMAIZUMI T, HORIYA Y, FUJISAWA T, SHIBATA T, TANABASHI S, ETAL. A CASE OF DIABETIC KETOACIDOSIS IN A PATIENT WITH POSITIVE ANTI-INSULIN ANTIBODY AND ANTI-INSULIN RECEPTOR ANTIBODY.",86.0,YR,,M,Y,,,20180407.0,,MD,JP,JP,2018,Q2,Elderly
146218303,14621830,3,SS,DULAGLUTIDE(GENETICAL RECOMBINATION),DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,3,F,201710.0,20180330.0,20180310,20180407,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001154",BOEHRINGER INGELHEIM,"TOHARA R, IMAIZUMI T, HORIYA Y, FUJISAWA T, SHIBATA T, TANABASHI S, ETAL. A CASE OF DIABETIC KETOACIDOSIS IN A PATIENT WITH POSITIVE ANTI-INSULIN ANTIBODY AND ANTI-INSULIN RECEPTOR ANTIBODY.",86.0,YR,,M,Y,,,20180407.0,,MD,JP,JP,2018,Q2,Elderly
147197901,14719790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1 DF, WEEKLY (1/W)",2.0,DF,,,,,125469.0,1.0,DF,,/wk,2018,Q2,Supraventricular tachycardia,,2018,Q2,1,I,20170914.0,20180329.0,20180405,20180405,EXP,GB-MHRA-EYC 00176174,GB-ELI_LILLY_AND_COMPANY-GB201803013889,ELI LILLY AND CO,,68.0,YR,,F,Y,,,20180405.0,,CN,GB,GB,2018,Q2,Elderly
147596882,14759688,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,U,,,,1.5,MG,INJECTION,,2018,Q2,Arthralgia,,2018,Q2,2,F,201712.0,20180413.0,20180413,20180424,EXP,,US-ELI_LILLY_AND_COMPANY-US201804003468,ELI LILLY AND CO,,62.0,YR,,F,Y,,,20180424.0,,CN,US,US,2018,Q2,Adult
147596882,14759688,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,U,,,,1.5,MG,INJECTION,,2018,Q2,Arthropathy,,2018,Q2,2,F,201712.0,20180413.0,20180413,20180424,EXP,,US-ELI_LILLY_AND_COMPANY-US201804003468,ELI LILLY AND CO,,62.0,YR,,F,Y,,,20180424.0,,CN,US,US,2018,Q2,Adult
147596882,14759688,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,U,,,,1.5,MG,INJECTION,,2018,Q2,Back pain,,2018,Q2,2,F,201712.0,20180413.0,20180413,20180424,EXP,,US-ELI_LILLY_AND_COMPANY-US201804003468,ELI LILLY AND CO,,62.0,YR,,F,Y,,,20180424.0,,CN,US,US,2018,Q2,Adult
147596882,14759688,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,U,,,,1.5,MG,INJECTION,,2018,Q2,Gait inability,,2018,Q2,2,F,201712.0,20180413.0,20180413,20180424,EXP,,US-ELI_LILLY_AND_COMPANY-US201804003468,ELI LILLY AND CO,,62.0,YR,,F,Y,,,20180424.0,,CN,US,US,2018,Q2,Adult
147596882,14759688,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,U,,,,1.5,MG,INJECTION,,2018,Q2,General physical health deterioration,,2018,Q2,2,F,201712.0,20180413.0,20180413,20180424,EXP,,US-ELI_LILLY_AND_COMPANY-US201804003468,ELI LILLY AND CO,,62.0,YR,,F,Y,,,20180424.0,,CN,US,US,2018,Q2,Adult
147596882,14759688,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,U,,,,1.5,MG,INJECTION,,2018,Q2,Malaise,,2018,Q2,2,F,201712.0,20180413.0,20180413,20180424,EXP,,US-ELI_LILLY_AND_COMPANY-US201804003468,ELI LILLY AND CO,,62.0,YR,,F,Y,,,20180424.0,,CN,US,US,2018,Q2,Adult
147833592,14783359,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNK",,,U,,,,,0.75,MG,,,2018,Q2,Blood glucose increased,,2018,Q2,2,F,,20180608.0,20180420,20180612,EXP,,PHJP2018JP008813,NOVARTIS,"HONJO S, ABE M, IWASAKI Y, IWASAKI K, AYANO S, IKEDA H ET AL.. EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR AGGRAVATION OF DIABETES MELLITUS CAUSED BY PASIREOTIDE. JOURNAL OF THE JAPAN ENDOCRINE SOCIETY; THE 91ST ANNUAL MEETING OF THE JAPAN END. 2018;94:404",61.0,YR,,F,Y,,,20180612.0,,OT,JP,JP,2018,Q2,Adult
147833592,14783359,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNK",,,U,,,,,0.75,MG,,,2018,Q2,Diabetes mellitus,,2018,Q2,2,F,,20180608.0,20180420,20180612,EXP,,PHJP2018JP008813,NOVARTIS,"HONJO S, ABE M, IWASAKI Y, IWASAKI K, AYANO S, IKEDA H ET AL.. EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR AGGRAVATION OF DIABETES MELLITUS CAUSED BY PASIREOTIDE. JOURNAL OF THE JAPAN ENDOCRINE SOCIETY; THE 91ST ANNUAL MEETING OF THE JAPAN END. 2018;94:404",61.0,YR,,F,Y,,,20180612.0,,OT,JP,JP,2018,Q2,Adult
147833592,14783359,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNK",,,U,,,,,0.75,MG,,,2018,Q2,Impaired insulin secretion,,2018,Q2,2,F,,20180608.0,20180420,20180612,EXP,,PHJP2018JP008813,NOVARTIS,"HONJO S, ABE M, IWASAKI Y, IWASAKI K, AYANO S, IKEDA H ET AL.. EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR AGGRAVATION OF DIABETES MELLITUS CAUSED BY PASIREOTIDE. JOURNAL OF THE JAPAN ENDOCRINE SOCIETY; THE 91ST ANNUAL MEETING OF THE JAPAN END. 2018;94:404",61.0,YR,,F,Y,,,20180612.0,,OT,JP,JP,2018,Q2,Adult
147833592,14783359,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNK",,,U,,,,,0.75,MG,,,2018,Q2,Postprandial hypoglycaemia,,2018,Q2,2,F,,20180608.0,20180420,20180612,EXP,,PHJP2018JP008813,NOVARTIS,"HONJO S, ABE M, IWASAKI Y, IWASAKI K, AYANO S, IKEDA H ET AL.. EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR AGGRAVATION OF DIABETES MELLITUS CAUSED BY PASIREOTIDE. JOURNAL OF THE JAPAN ENDOCRINE SOCIETY; THE 91ST ANNUAL MEETING OF THE JAPAN END. 2018;94:404",61.0,YR,,F,Y,,,20180612.0,,OT,JP,JP,2018,Q2,Adult
148077941,14807794,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,1.5,MG,,/wk,2018,Q2,Hyperglycaemia,,2018,Q2,1,I,20171114.0,20180423.0,20180425,20180425,EXP,GB-MHRA-MIDB-4644A911-B1D9-4E72-8EB4-E151E4704881,GB-ELI_LILLY_AND_COMPANY-GB201804012286,ELI LILLY AND CO,,57.0,YR,,,Y,,,20180425.0,,CN,GB,GB,2018,Q2,Adult
148077941,14807794,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,1.5,MG,,/wk,2018,Q2,Nausea,,2018,Q2,1,I,20171114.0,20180423.0,20180425,20180425,EXP,GB-MHRA-MIDB-4644A911-B1D9-4E72-8EB4-E151E4704881,GB-ELI_LILLY_AND_COMPANY-GB201804012286,ELI LILLY AND CO,,57.0,YR,,,Y,,,20180425.0,,CN,GB,GB,2018,Q2,Adult
148077941,14807794,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,1.5,MG,,/wk,2018,Q2,Vomiting,,2018,Q2,1,I,20171114.0,20180423.0,20180425,20180425,EXP,GB-MHRA-MIDB-4644A911-B1D9-4E72-8EB4-E151E4704881,GB-ELI_LILLY_AND_COMPANY-GB201804012286,ELI LILLY AND CO,,57.0,YR,,,Y,,,20180425.0,,CN,GB,GB,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Abdominal discomfort,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Abdominal pain,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Back pain,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Decreased appetite,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Gastrooesophageal reflux disease,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Helicobacter test positive,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Hiatus hernia,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Hyperglycaemia,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Hypophagia,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Melaena,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Nausea,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Pain,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148328521,14832852,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2018,Q2,Small intestinal obstruction,,2018,Q2,1,I,20180121.0,,20180411,20180411,DIR,,,FDA-CTU,,64.0,YR,,F,N,60.05,KG,20180411.0,N,PH,US,US,2018,Q2,Adult
148422851,14842285,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U,,,125469.0,,,INJECTION,,2018,Q2,Hypoglycaemia,,2018,Q2,1,I,,20180424.0,20180503,20180503,EXP,,US-ELI_LILLY_AND_COMPANY-US201804013977,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20180503.0,,CN,US,US,2018,Q2,Adult
148422851,14842285,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U,,,125469.0,,,INJECTION,,2018,Q2,Loss of consciousness,,2018,Q2,1,I,,20180424.0,20180503,20180503,EXP,,US-ELI_LILLY_AND_COMPANY-US201804013977,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20180503.0,,CN,US,US,2018,Q2,Adult
148491342,14849134,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,125469.0,,,INJECTION,,2018,Q2,Drug dose omission,,2018,Q2,2,F,201710.0,20180504.0,20180504,20180518,EXP,,US-ELI_LILLY_AND_COMPANY-US201804013319,ELI LILLY AND CO,,45.0,YR,,M,Y,,,20180518.0,,CN,US,US,2018,Q2,Adult
148491342,14849134,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,125469.0,,,INJECTION,,2018,Q2,Off label use,,2018,Q2,2,F,201710.0,20180504.0,20180504,20180518,EXP,,US-ELI_LILLY_AND_COMPANY-US201804013319,ELI LILLY AND CO,,45.0,YR,,M,Y,,,20180518.0,,CN,US,US,2018,Q2,Adult
148491342,14849134,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,125469.0,,,INJECTION,,2018,Q2,Weight decreased,,2018,Q2,2,F,201710.0,20180504.0,20180504,20180518,EXP,,US-ELI_LILLY_AND_COMPANY-US201804013319,ELI LILLY AND CO,,45.0,YR,,M,Y,,,20180518.0,,CN,US,US,2018,Q2,Adult
149122121,14912212,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,"1 DF, UNK",,,U,U,,,,1.0,DF,,,2018,Q2,Atrioventricular block first degree,,2018,Q2,1,I,20180223.0,20180504.0,20180518,20180518,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-173150,RANBAXY,,40.0,YR,,F,Y,97.0,KG,20180518.0,,OT,GB,FR,2018,Q2,Adult
149122121,14912212,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,"1 DF, UNK",,,U,U,,,,1.0,DF,,,2018,Q2,Coma,,2018,Q2,1,I,20180223.0,20180504.0,20180518,20180518,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-173150,RANBAXY,,40.0,YR,,F,Y,97.0,KG,20180518.0,,OT,GB,FR,2018,Q2,Adult
149122121,14912212,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,"1 DF, UNK",,,U,U,,,,1.0,DF,,,2018,Q2,Hypovolaemic shock,,2018,Q2,1,I,20180223.0,20180504.0,20180518,20180518,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-173150,RANBAXY,,40.0,YR,,F,Y,97.0,KG,20180518.0,,OT,GB,FR,2018,Q2,Adult
149122121,14912212,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,"1 DF, UNK",,,U,U,,,,1.0,DF,,,2018,Q2,Hypoxia,,2018,Q2,1,I,20180223.0,20180504.0,20180518,20180518,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-173150,RANBAXY,,40.0,YR,,F,Y,97.0,KG,20180518.0,,OT,GB,FR,2018,Q2,Adult
149122121,14912212,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,"1 DF, UNK",,,U,U,,,,1.0,DF,,,2018,Q2,Miosis,,2018,Q2,1,I,20180223.0,20180504.0,20180518,20180518,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-173150,RANBAXY,,40.0,YR,,F,Y,97.0,KG,20180518.0,,OT,GB,FR,2018,Q2,Adult
149410491,14941049,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, UNKNOWN",,,,U, C763009F,,125469.0,0.75,MG,INJECTION,,2018,Q2,Acne,,2018,Q2,1,I,201804.0,20180514.0,20180525,20180525,EXP,,IN-ELI_LILLY_AND_COMPANY-IN201805006632,ELI LILLY AND CO,,36.0,YR,,F,Y,122.7,KG,20180525.0,,CN,IN,IN,2018,Q2,Adult
149410491,14941049,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, UNKNOWN",,,,U, C763009F,,125469.0,0.75,MG,INJECTION,,2018,Q2,Injection site erythema,,2018,Q2,1,I,201804.0,20180514.0,20180525,20180525,EXP,,IN-ELI_LILLY_AND_COMPANY-IN201805006632,ELI LILLY AND CO,,36.0,YR,,F,Y,122.7,KG,20180525.0,,CN,IN,IN,2018,Q2,Adult
149410491,14941049,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, UNKNOWN",,,,U, C763009F,,125469.0,0.75,MG,INJECTION,,2018,Q2,Weight decreased,,2018,Q2,1,I,201804.0,20180514.0,20180525,20180525,EXP,,IN-ELI_LILLY_AND_COMPANY-IN201805006632,ELI LILLY AND CO,,36.0,YR,,F,Y,122.7,KG,20180525.0,,CN,IN,IN,2018,Q2,Adult
149410491,14941049,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,,U, C763009F,,125469.0,1.5,MG,INJECTION,,2018,Q2,Acne,,2018,Q2,1,I,201804.0,20180514.0,20180525,20180525,EXP,,IN-ELI_LILLY_AND_COMPANY-IN201805006632,ELI LILLY AND CO,,36.0,YR,,F,Y,122.7,KG,20180525.0,,CN,IN,IN,2018,Q2,Adult
149410491,14941049,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,,U, C763009F,,125469.0,1.5,MG,INJECTION,,2018,Q2,Injection site erythema,,2018,Q2,1,I,201804.0,20180514.0,20180525,20180525,EXP,,IN-ELI_LILLY_AND_COMPANY-IN201805006632,ELI LILLY AND CO,,36.0,YR,,F,Y,122.7,KG,20180525.0,,CN,IN,IN,2018,Q2,Adult
149410491,14941049,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,,U, C763009F,,125469.0,1.5,MG,INJECTION,,2018,Q2,Weight decreased,,2018,Q2,1,I,201804.0,20180514.0,20180525,20180525,EXP,,IN-ELI_LILLY_AND_COMPANY-IN201805006632,ELI LILLY AND CO,,36.0,YR,,F,Y,122.7,KG,20180525.0,,CN,IN,IN,2018,Q2,Adult
149607131,14960713,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2018,Q2,Accidental exposure to product,,2018,Q2,1,I,20180107.0,20180108.0,20180531,20180531,PER,,US-AMGEN-USASP2018002838,AMGEN,,65.0,YR,E,F,Y,,,20180531.0,,MD,US,US,2018,Q2,Elderly
149607131,14960713,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2018,Q2,Drug dose omission,,2018,Q2,1,I,20180107.0,20180108.0,20180531,20180531,PER,,US-AMGEN-USASP2018002838,AMGEN,,65.0,YR,E,F,Y,,,20180531.0,,MD,US,US,2018,Q2,Elderly
149635741,14963574,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, EVERY 3 WEEKS",,,,,,,,1.0,DF,,,2018,Q2,Atrioventricular block first degree,,2018,Q2,1,I,20180223.0,20180529.0,20180601,20180601,EXP,FR-AFSSAPS-PA20181098,FR-PFIZER INC-2018220110,PFIZER,,40.0,YR,,F,Y,97.0,KG,20180601.0,,MD,FR,FR,2018,Q2,Adult
149635741,14963574,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, EVERY 3 WEEKS",,,,,,,,1.0,DF,,,2018,Q2,Coma,,2018,Q2,1,I,20180223.0,20180529.0,20180601,20180601,EXP,FR-AFSSAPS-PA20181098,FR-PFIZER INC-2018220110,PFIZER,,40.0,YR,,F,Y,97.0,KG,20180601.0,,MD,FR,FR,2018,Q2,Adult
149635741,14963574,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, EVERY 3 WEEKS",,,,,,,,1.0,DF,,,2018,Q2,Hypovolaemic shock,,2018,Q2,1,I,20180223.0,20180529.0,20180601,20180601,EXP,FR-AFSSAPS-PA20181098,FR-PFIZER INC-2018220110,PFIZER,,40.0,YR,,F,Y,97.0,KG,20180601.0,,MD,FR,FR,2018,Q2,Adult
149635741,14963574,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, EVERY 3 WEEKS",,,,,,,,1.0,DF,,,2018,Q2,Hypoxia,,2018,Q2,1,I,20180223.0,20180529.0,20180601,20180601,EXP,FR-AFSSAPS-PA20181098,FR-PFIZER INC-2018220110,PFIZER,,40.0,YR,,F,Y,97.0,KG,20180601.0,,MD,FR,FR,2018,Q2,Adult
149635741,14963574,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, EVERY 3 WEEKS",,,,,,,,1.0,DF,,,2018,Q2,Miosis,,2018,Q2,1,I,20180223.0,20180529.0,20180601,20180601,EXP,FR-AFSSAPS-PA20181098,FR-PFIZER INC-2018220110,PFIZER,,40.0,YR,,F,Y,97.0,KG,20180601.0,,MD,FR,FR,2018,Q2,Adult
149697581,14969758,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,,,,99.0,0.75,MG,,QW,2018,Q2,Angioedema,,2018,Q2,1,I,20180505.0,,20180511,20180511,DIR,,,FDA-CTU,,62.0,YR,,F,N,,,20180511.0,N,PH,US,US,2018,Q2,Adult
149739421,14973942,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.5,ML,,QW,2018,Q2,Acarodermatitis,,2018,Q2,1,I,20180502.0,,20180514,20180514,DIR,,,FDA-CTU,,77.0,YR,,M,N,106.5,KG,20180514.0,N,PH,US,US,2018,Q2,Elderly
149739421,14973942,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.5,ML,,QW,2018,Q2,Pruritus,,2018,Q2,1,I,20180502.0,,20180514,20180514,DIR,,,FDA-CTU,,77.0,YR,,M,N,106.5,KG,20180514.0,N,PH,US,US,2018,Q2,Elderly
149739421,14973942,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.5,ML,,QW,2018,Q2,Rash,,2018,Q2,1,I,20180502.0,,20180514,20180514,DIR,,,FDA-CTU,,77.0,YR,,M,N,106.5,KG,20180514.0,N,PH,US,US,2018,Q2,Elderly
149739421,14973942,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.5,ML,,QW,2018,Q2,Skin abrasion,,2018,Q2,1,I,20180502.0,,20180514,20180514,DIR,,,FDA-CTU,,77.0,YR,,M,N,106.5,KG,20180514.0,N,PH,US,US,2018,Q2,Elderly
149941431,14994143,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,,,2018,Q2,Colitis ulcerative,,2018,Q2,1,I,,20180605.0,20180611,20180611,EXP,,CA-ABBVIE-18S-028-2382768-00,ABBVIE,,73.0,YR,,F,Y,,,20180611.0,,CN,CA,CA,2018,Q2,Elderly
149941431,14994143,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,,,2018,Q2,Drug ineffective,,2018,Q2,1,I,,20180605.0,20180611,20180611,EXP,,CA-ABBVIE-18S-028-2382768-00,ABBVIE,,73.0,YR,,F,Y,,,20180611.0,,CN,CA,CA,2018,Q2,Elderly
150200251,15020025,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,,,,,,,,,1.0,DF,,,2018,Q2,Atrioventricular block first degree,,2018,Q2,1,I,20180223.0,20180612.0,20180618,20180618,EXP,FR-AFSSAPS-PA20181098,FR-TEVA-2018-FR-907371,TEVA,,40.0,YR,,F,Y,97.0,KG,20180618.0,,MD,FR,FR,2018,Q2,Adult
150200251,15020025,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,,,,,,,,,1.0,DF,,,2018,Q2,Coma,,2018,Q2,1,I,20180223.0,20180612.0,20180618,20180618,EXP,FR-AFSSAPS-PA20181098,FR-TEVA-2018-FR-907371,TEVA,,40.0,YR,,F,Y,97.0,KG,20180618.0,,MD,FR,FR,2018,Q2,Adult
150200251,15020025,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,,,,,,,,,1.0,DF,,,2018,Q2,Hypovolaemic shock,,2018,Q2,1,I,20180223.0,20180612.0,20180618,20180618,EXP,FR-AFSSAPS-PA20181098,FR-TEVA-2018-FR-907371,TEVA,,40.0,YR,,F,Y,97.0,KG,20180618.0,,MD,FR,FR,2018,Q2,Adult
150200251,15020025,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,,,,,,,,,1.0,DF,,,2018,Q2,Hypoxia,,2018,Q2,1,I,20180223.0,20180612.0,20180618,20180618,EXP,FR-AFSSAPS-PA20181098,FR-TEVA-2018-FR-907371,TEVA,,40.0,YR,,F,Y,97.0,KG,20180618.0,,MD,FR,FR,2018,Q2,Adult
150200251,15020025,16,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Ophthalmic,,,,,,,,,1.0,DF,,,2018,Q2,Miosis,,2018,Q2,1,I,20180223.0,20180612.0,20180618,20180618,EXP,FR-AFSSAPS-PA20181098,FR-TEVA-2018-FR-907371,TEVA,,40.0,YR,,F,Y,97.0,KG,20180618.0,,MD,FR,FR,2018,Q2,Adult
150236721,15023672,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,D,,,,,,,,,2018,Q2,Colitis ulcerative,,2018,Q2,1,I,,20180605.0,20180618,20180618,EXP,,CA-MYLANLABS-2018M1039852,MYLAN,,73.0,YR,,F,Y,,,20180613.0,,CN,CA,CA,2018,Q2,Elderly
150236721,15023672,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,D,,,,,,,,,2018,Q2,Drug ineffective,,2018,Q2,1,I,,20180605.0,20180618,20180618,EXP,,CA-MYLANLABS-2018M1039852,MYLAN,,73.0,YR,,F,Y,,,20180613.0,,CN,CA,CA,2018,Q2,Elderly
150484921,15048492,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,N,,,,,1.5,MG,,/wk,2018,Q2,Hyperamylasaemia,,2018,Q2,1,I,20170905.0,20180614.0,20180622,20180622,EXP,ES-AEMPS-362747,ES-BAUSCH-BL-2018-016964,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20180622.0,,MD,ES,ES,2018,Q2,Adult
150484921,15048492,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,N,,,,,1.5,MG,,/wk,2018,Q2,Lipase increased,,2018,Q2,1,I,20170905.0,20180614.0,20180622,20180622,EXP,ES-AEMPS-362747,ES-BAUSCH-BL-2018-016964,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20180622.0,,MD,ES,ES,2018,Q2,Adult
150501832,15050183,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, QW",,,,,,,,0.75,MG,,,2018,Q2,Cough,,2018,Q2,2,F,20180402.0,20180622.0,20180622,20180628,PER,,US-UNITED THERAPEUTICS-UNT-2018-008972,UNITED THERAPEUTICS,,76.0,YR,,F,Y,,,20180628.0,,CN,US,US,2018,Q2,Elderly
150501832,15050183,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, QW",,,,,,,,0.75,MG,,,2018,Q2,Diarrhoea,,2018,Q2,2,F,20180402.0,20180622.0,20180622,20180628,PER,,US-UNITED THERAPEUTICS-UNT-2018-008972,UNITED THERAPEUTICS,,76.0,YR,,F,Y,,,20180628.0,,CN,US,US,2018,Q2,Elderly
150501832,15050183,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, QW",,,,,,,,0.75,MG,,,2018,Q2,Sneezing,,2018,Q2,2,F,20180402.0,20180622.0,20180622,20180628,PER,,US-UNITED THERAPEUTICS-UNT-2018-008972,UNITED THERAPEUTICS,,76.0,YR,,F,Y,,,20180628.0,,CN,US,US,2018,Q2,Elderly
150510441,15051044,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q2,Drug ineffective,,2018,Q2,1,I,201804.0,20180430.0,20180622,20180622,PER,,US-ASTELLAS-2018US020916,ASTELLAS,,71.0,YR,,M,Y,,,20180622.0,,CN,US,US,2018,Q2,Elderly
150510441,15051044,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q2,Fatigue,,2018,Q2,1,I,201804.0,20180430.0,20180622,20180622,PER,,US-ASTELLAS-2018US020916,ASTELLAS,,71.0,YR,,M,Y,,,20180622.0,,CN,US,US,2018,Q2,Elderly
150532921,15053292,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",3.0,MG,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q2,Decreased appetite,,2018,Q2,1,I,20180527.0,20180611.0,20180622,20180622,EXP,IT-MINISAL02-479952,IT-ELI_LILLY_AND_COMPANY-IT201806005074,ELI LILLY AND CO,,68.0,YR,,M,Y,110.0,KG,20180622.0,,CN,IT,IT,2018,Q2,Elderly
150532921,15053292,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",3.0,MG,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q2,Dehydration,,2018,Q2,1,I,20180527.0,20180611.0,20180622,20180622,EXP,IT-MINISAL02-479952,IT-ELI_LILLY_AND_COMPANY-IT201806005074,ELI LILLY AND CO,,68.0,YR,,M,Y,110.0,KG,20180622.0,,CN,IT,IT,2018,Q2,Elderly
150532921,15053292,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",3.0,MG,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q2,Diarrhoea,,2018,Q2,1,I,20180527.0,20180611.0,20180622,20180622,EXP,IT-MINISAL02-479952,IT-ELI_LILLY_AND_COMPANY-IT201806005074,ELI LILLY AND CO,,68.0,YR,,M,Y,110.0,KG,20180622.0,,CN,IT,IT,2018,Q2,Elderly
150532921,15053292,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",3.0,MG,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q2,Nephrolithiasis,,2018,Q2,1,I,20180527.0,20180611.0,20180622,20180622,EXP,IT-MINISAL02-479952,IT-ELI_LILLY_AND_COMPANY-IT201806005074,ELI LILLY AND CO,,68.0,YR,,M,Y,110.0,KG,20180622.0,,CN,IT,IT,2018,Q2,Elderly
150532921,15053292,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",3.0,MG,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q2,Renal colic,,2018,Q2,1,I,20180527.0,20180611.0,20180622,20180622,EXP,IT-MINISAL02-479952,IT-ELI_LILLY_AND_COMPANY-IT201806005074,ELI LILLY AND CO,,68.0,YR,,M,Y,110.0,KG,20180622.0,,CN,IT,IT,2018,Q2,Elderly
150532921,15053292,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",3.0,MG,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q2,Vomiting,,2018,Q2,1,I,20180527.0,20180611.0,20180622,20180622,EXP,IT-MINISAL02-479952,IT-ELI_LILLY_AND_COMPANY-IT201806005074,ELI LILLY AND CO,,68.0,YR,,M,Y,110.0,KG,20180622.0,,CN,IT,IT,2018,Q2,Elderly
150578191,15057819,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, EVERY WEEK",,,N,U, UNK,,,1.5,MG,,,2018,Q2,Hyperamylasaemia,,2018,Q2,1,I,20170905.0,20180611.0,20180625,20180625,EXP,,ES-AUROBINDO-AUR-APL-2018-032010,AUROBINDO,,53.0,YR,,M,Y,,,20180625.0,,MD,ES,ES,2018,Q2,Adult
150578191,15057819,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, EVERY WEEK",,,N,U, UNK,,,1.5,MG,,,2018,Q2,Lipase increased,,2018,Q2,1,I,20170905.0,20180611.0,20180625,20180625,EXP,,ES-AUROBINDO-AUR-APL-2018-032010,AUROBINDO,,53.0,YR,,M,Y,,,20180625.0,,MD,ES,ES,2018,Q2,Adult
150584141,15058414,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNK",,,N,,,,,1.5,MG,INJECTION,,2018,Q2,Hyperamylasaemia,,2018,Q2,1,I,20170905.0,20180611.0,20180625,20180625,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-056475,BRISTOL MYERS SQUIBB,,53.0,YR,,M,Y,,,20180625.0,,MD,ES,ES,2018,Q2,Adult
150584141,15058414,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNK",,,N,,,,,1.5,MG,INJECTION,,2018,Q2,Lipase increased,,2018,Q2,1,I,20170905.0,20180611.0,20180625,20180625,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-056475,BRISTOL MYERS SQUIBB,,53.0,YR,,M,Y,,,20180625.0,,MD,ES,ES,2018,Q2,Adult
137298304,13729830,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q3,Gastrointestinal haemorrhage,,2018,Q3,4,F,20160602.0,20180720.0,20170707,20180803,PER,,US-JNJFOC-20170504628,JANSSEN,,69.0,YR,E,M,Y,,,20180803.0,,CN,US,US,2018,Q3,Elderly
137298304,13729830,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q3,Rectal haemorrhage,,2018,Q3,4,F,20160602.0,20180720.0,20170707,20180803,PER,,US-JNJFOC-20170504628,JANSSEN,,69.0,YR,E,M,Y,,,20180803.0,,CN,US,US,2018,Q3,Elderly
144726253,14472625,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2018,Q3,Acute coronary syndrome,,2018,Q3,3,F,,20180719.0,20180201,20180730,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-008421,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,89.0,KG,20180730.0,,CN,JP,JP,2018,Q3,Adult
150133312,15013331,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intradermal,"1.5 MG, EVERY 7 DAYS",,,,U,,,,1.5,MG,,,2018,Q3,Death,,2018,Q3,2,F,20180602.0,20180918.0,20180614,20180927,EXP,,US-ACTELION-A-US2018-173090,ACTELION,,59.0,YR,A,F,Y,,,20180927.0,,OT,US,US,2018,Q3,Adult
150133312,15013331,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intradermal,"1.5 MG, EVERY 7 DAYS",,,,U,,,,1.5,MG,,,2018,Q3,Dyspnoea,,2018,Q3,2,F,20180602.0,20180918.0,20180614,20180927,EXP,,US-ACTELION-A-US2018-173090,ACTELION,,59.0,YR,A,F,Y,,,20180927.0,,OT,US,US,2018,Q3,Adult
150133312,15013331,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intradermal,"1.5 MG, EVERY 7 DAYS",,,,U,,,,1.5,MG,,,2018,Q3,Oxygen consumption increased,,2018,Q3,2,F,20180602.0,20180918.0,20180614,20180927,EXP,,US-ACTELION-A-US2018-173090,ACTELION,,59.0,YR,A,F,Y,,,20180927.0,,OT,US,US,2018,Q3,Adult
150309642,15030964,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, C876362D,,125469.0,0.75,MG,INJECTION,/wk,2018,Q3,Diarrhoea,,2018,Q3,2,F,20180528.0,20180618.0,20180619,20180712,PER,,US-ELI_LILLY_AND_COMPANY-US201806002372,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20180712.0,,CN,US,US,2018,Q3,Elderly
150309642,15030964,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, C876362D,,125469.0,0.75,MG,INJECTION,/wk,2018,Q3,Hunger,,2018,Q3,2,F,20180528.0,20180618.0,20180619,20180712,PER,,US-ELI_LILLY_AND_COMPANY-US201806002372,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20180712.0,,CN,US,US,2018,Q3,Elderly
150309642,15030964,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, C876362D,,125469.0,0.75,MG,INJECTION,/wk,2018,Q3,Nausea,,2018,Q3,2,F,20180528.0,20180618.0,20180619,20180712,PER,,US-ELI_LILLY_AND_COMPANY-US201806002372,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20180712.0,,CN,US,US,2018,Q3,Elderly
150309642,15030964,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, C876362D,,125469.0,0.75,MG,INJECTION,/wk,2018,Q3,Sciatica,,2018,Q3,2,F,20180528.0,20180618.0,20180619,20180712,PER,,US-ELI_LILLY_AND_COMPANY-US201806002372,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20180712.0,,CN,US,US,2018,Q3,Elderly
150309642,15030964,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,INJECTION,/wk,2018,Q3,Diarrhoea,,2018,Q3,2,F,20180528.0,20180618.0,20180619,20180712,PER,,US-ELI_LILLY_AND_COMPANY-US201806002372,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20180712.0,,CN,US,US,2018,Q3,Elderly
150309642,15030964,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,INJECTION,/wk,2018,Q3,Hunger,,2018,Q3,2,F,20180528.0,20180618.0,20180619,20180712,PER,,US-ELI_LILLY_AND_COMPANY-US201806002372,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20180712.0,,CN,US,US,2018,Q3,Elderly
150309642,15030964,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,INJECTION,/wk,2018,Q3,Nausea,,2018,Q3,2,F,20180528.0,20180618.0,20180619,20180712,PER,,US-ELI_LILLY_AND_COMPANY-US201806002372,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20180712.0,,CN,US,US,2018,Q3,Elderly
150309642,15030964,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,INJECTION,/wk,2018,Q3,Sciatica,,2018,Q3,2,F,20180528.0,20180618.0,20180619,20180712,PER,,US-ELI_LILLY_AND_COMPANY-US201806002372,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20180712.0,,CN,US,US,2018,Q3,Elderly
150342882,15034288,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q3,Pneumatosis intestinalis,,2018,Q3,2,F,,20180625.0,20180620,20180702,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003285",BOEHRINGER INGELHEIM,"TANAKA Y, ISOBE S, SATO S, IWAMURA H, CHIKAZAWA S, NIGAWARA T. 13 A CASE OF PNEUMATOSIS CYSTOIDES INTESTINALIS DEVELOPED DURING THERAPY WITH ALPHA?GLUCOSIDASE INHIBITORS.",9.0,DEC,,M,Y,,,20180702.0,,MD,JP,JP,2018,Q3,Child
150973271,15097327,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q3,Gastroenteritis viral,,2018,Q3,1,I,20180124.0,20180627.0,20180702,20180702,EXP,,GB-JNJFOC-20180639141,JANSSEN,,65.0,YR,A,F,Y,111.0,KG,20180702.0,,CN,GB,GB,2018,Q3,Elderly
151035361,15103536,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,Y,U,,,125469.0,1.5,MG,INJECTION,,2018,Q3,Supraventricular tachycardia,,2018,Q3,1,I,,20180621.0,20180703,20180703,EXP,,CO-ELI_LILLY_AND_COMPANY-CO201806011258,ELI LILLY AND CO,,40.0,YR,,F,Y,,,20180703.0,,CN,CO,CO,2018,Q3,Adult
151289561,15128956,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,USE AS DIRECTED,11.285714,DF,,,,,,1.0,DF,,,2018,Q3,Ischaemic stroke,,2018,Q3,1,I,20180629.0,20180710.0,20180711,20180711,EXP,GB-MHRA-TPP25801382C3810409YC1530267044461,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002348",BOEHRINGER INGELHEIM,,35.0,YR,,F,Y,68.0,KG,20180711.0,,PH,GB,GB,2018,Q3,Adult
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Asthenia,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Blood ketone body increased,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Body mass index abnormal,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Constipation,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Glycosylated haemoglobin increased,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Hyperglycaemia,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Malaise,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Malnutrition,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Metabolic disorder,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151304671,15130467,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U, UNK,,125469.0,,,,,2018,Q3,Weight decreased,,2018,Q3,1,I,,20180703.0,20180711,20180711,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201807003000,ELI LILLY AND CO,,87.0,YR,,F,Y,,,20180711.0,,CN,JP,JP,2018,Q3,Elderly
151308711,15130871,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,Y,U,,,125469.0,,,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,20160124.0,20180703.0,20180711,20180711,EXP,,US-ELI_LILLY_AND_COMPANY-US201807001840,ELI LILLY AND CO,,40.0,YR,,F,Y,,,20180711.0,,CN,US,US,2018,Q3,Adult
151450311,15145031,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,U,,,,,1.0,DF,,Q3W,2018,Q3,Atrioventricular block first degree,,2018,Q3,1,I,20180223.0,20180704.0,20180713,20180713,EXP,,PHHY2018FR045071,SANDOZ,,40.0,YR,,F,Y,97.0,KG,20180713.0,,OT,FR,FR,2018,Q3,Adult
151450311,15145031,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,U,,,,,1.0,DF,,Q3W,2018,Q3,Coma,,2018,Q3,1,I,20180223.0,20180704.0,20180713,20180713,EXP,,PHHY2018FR045071,SANDOZ,,40.0,YR,,F,Y,97.0,KG,20180713.0,,OT,FR,FR,2018,Q3,Adult
151450311,15145031,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,U,,,,,1.0,DF,,Q3W,2018,Q3,Hypovolaemic shock,,2018,Q3,1,I,20180223.0,20180704.0,20180713,20180713,EXP,,PHHY2018FR045071,SANDOZ,,40.0,YR,,F,Y,97.0,KG,20180713.0,,OT,FR,FR,2018,Q3,Adult
151450311,15145031,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,U,,,,,1.0,DF,,Q3W,2018,Q3,Hypoxia,,2018,Q3,1,I,20180223.0,20180704.0,20180713,20180713,EXP,,PHHY2018FR045071,SANDOZ,,40.0,YR,,F,Y,97.0,KG,20180713.0,,OT,FR,FR,2018,Q3,Adult
151450311,15145031,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,U,,,,,1.0,DF,,Q3W,2018,Q3,Miosis,,2018,Q3,1,I,20180223.0,20180704.0,20180713,20180713,EXP,,PHHY2018FR045071,SANDOZ,,40.0,YR,,F,Y,97.0,KG,20180713.0,,OT,FR,FR,2018,Q3,Adult
151455431,15145543,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNK",,,,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2018,Q3,Abnormal loss of weight,,2018,Q3,1,I,20180425.0,20180710.0,20180713,20180713,EXP,GB-MHRA-EYC 00181805,GB-ELI_LILLY_AND_COMPANY-GB201807004974,ELI LILLY AND CO,,69.0,YR,,F,Y,88.0,KG,20180713.0,,CN,GB,GB,2018,Q3,Elderly
151455431,15145543,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNK",,,,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2018,Q3,Cough,,2018,Q3,1,I,20180425.0,20180710.0,20180713,20180713,EXP,GB-MHRA-EYC 00181805,GB-ELI_LILLY_AND_COMPANY-GB201807004974,ELI LILLY AND CO,,69.0,YR,,F,Y,88.0,KG,20180713.0,,CN,GB,GB,2018,Q3,Elderly
151455431,15145543,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNK",,,,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2018,Q3,Dyspnoea,,2018,Q3,1,I,20180425.0,20180710.0,20180713,20180713,EXP,GB-MHRA-EYC 00181805,GB-ELI_LILLY_AND_COMPANY-GB201807004974,ELI LILLY AND CO,,69.0,YR,,F,Y,88.0,KG,20180713.0,,CN,GB,GB,2018,Q3,Elderly
151455431,15145543,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNK",,,,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2018,Q3,Musculoskeletal chest pain,,2018,Q3,1,I,20180425.0,20180710.0,20180713,20180713,EXP,GB-MHRA-EYC 00181805,GB-ELI_LILLY_AND_COMPANY-GB201807004974,ELI LILLY AND CO,,69.0,YR,,F,Y,88.0,KG,20180713.0,,CN,GB,GB,2018,Q3,Elderly
151455431,15145543,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNK",,,,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2018,Q3,Pancreatic carcinoma,,2018,Q3,1,I,20180425.0,20180710.0,20180713,20180713,EXP,GB-MHRA-EYC 00181805,GB-ELI_LILLY_AND_COMPANY-GB201807004974,ELI LILLY AND CO,,69.0,YR,,F,Y,88.0,KG,20180713.0,,CN,GB,GB,2018,Q3,Elderly
152001981,15200198,1,PS,Dulaglutide 0.75mg,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE,/wk,2018,Q3,Underdose,,2018,Q3,1,I,20180718.0,20180720.0,20180726,20180726,PER,,US-ELI_LILLY_AND_COMPANY-US201807010622,ELI LILLY AND CO,,48.0,YR,,F,Y,,,20180726.0,,CN,US,US,2018,Q3,Adult
152067691,15206769,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Decreased appetite,,2018,Q3,1,I,201801.0,20180718.0,20180727,20180727,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201807010509,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20180727.0,,CN,GR,GR,2018,Q3,Adult
152067691,15206769,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Diarrhoea,,2018,Q3,1,I,201801.0,20180718.0,20180727,20180727,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201807010509,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20180727.0,,CN,GR,GR,2018,Q3,Adult
152067691,15206769,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Nausea,,2018,Q3,1,I,201801.0,20180718.0,20180727,20180727,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201807010509,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20180727.0,,CN,GR,GR,2018,Q3,Adult
152067691,15206769,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Weight decreased,,2018,Q3,1,I,201801.0,20180718.0,20180727,20180727,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201807010509,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20180727.0,,CN,GR,GR,2018,Q3,Adult
152067691,15206769,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNK",,,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Decreased appetite,,2018,Q3,1,I,201801.0,20180718.0,20180727,20180727,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201807010509,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20180727.0,,CN,GR,GR,2018,Q3,Adult
152067691,15206769,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNK",,,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Diarrhoea,,2018,Q3,1,I,201801.0,20180718.0,20180727,20180727,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201807010509,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20180727.0,,CN,GR,GR,2018,Q3,Adult
152067691,15206769,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNK",,,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Nausea,,2018,Q3,1,I,201801.0,20180718.0,20180727,20180727,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201807010509,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20180727.0,,CN,GR,GR,2018,Q3,Adult
152067691,15206769,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNK",,,Y,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Weight decreased,,2018,Q3,1,I,201801.0,20180718.0,20180727,20180727,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201807010509,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20180727.0,,CN,GR,GR,2018,Q3,Adult
152109322,15210932,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2018,Q3,Altered state of consciousness,,2018,Q3,2,F,2013.0,20180830.0,20180728,20180911,EXP,,JP-SA-2018SA196482,SANOFI AVENTIS,"IMAIZUMI T, SHIBATA T, HORITANI Y, FUJISAWA T, TANAHASHI S. A CASE OF ANTI?INSULIN ANTIBODY/ANTI?INSULIN RECEPTOR ANTIBODY POSITIVE DIABETES IN WHICH COMBINATION THERAPY WITH INSULIN ASPART AND VOGLIBOSE WAS EFFECTIVE. T15/DIABETES/(ISSN:0021?437X)? THE 61ST ANNUAL MEETING OF THE JAPAN DIABETES SOC. 2018?61:S255",86.0,YR,E,M,Y,,,20180911.0,,MD,JP,JP,2018,Q3,Elderly
152109322,15210932,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2018,Q3,Anti-insulin antibody positive,,2018,Q3,2,F,2013.0,20180830.0,20180728,20180911,EXP,,JP-SA-2018SA196482,SANOFI AVENTIS,"IMAIZUMI T, SHIBATA T, HORITANI Y, FUJISAWA T, TANAHASHI S. A CASE OF ANTI?INSULIN ANTIBODY/ANTI?INSULIN RECEPTOR ANTIBODY POSITIVE DIABETES IN WHICH COMBINATION THERAPY WITH INSULIN ASPART AND VOGLIBOSE WAS EFFECTIVE. T15/DIABETES/(ISSN:0021?437X)? THE 61ST ANNUAL MEETING OF THE JAPAN DIABETES SOC. 2018?61:S255",86.0,YR,E,M,Y,,,20180911.0,,MD,JP,JP,2018,Q3,Elderly
152109322,15210932,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,2,F,2013.0,20180830.0,20180728,20180911,EXP,,JP-SA-2018SA196482,SANOFI AVENTIS,"IMAIZUMI T, SHIBATA T, HORITANI Y, FUJISAWA T, TANAHASHI S. A CASE OF ANTI?INSULIN ANTIBODY/ANTI?INSULIN RECEPTOR ANTIBODY POSITIVE DIABETES IN WHICH COMBINATION THERAPY WITH INSULIN ASPART AND VOGLIBOSE WAS EFFECTIVE. T15/DIABETES/(ISSN:0021?437X)? THE 61ST ANNUAL MEETING OF THE JAPAN DIABETES SOC. 2018?61:S255",86.0,YR,E,M,Y,,,20180911.0,,MD,JP,JP,2018,Q3,Elderly
152109322,15210932,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2018,Q3,Hypoglycaemia,,2018,Q3,2,F,2013.0,20180830.0,20180728,20180911,EXP,,JP-SA-2018SA196482,SANOFI AVENTIS,"IMAIZUMI T, SHIBATA T, HORITANI Y, FUJISAWA T, TANAHASHI S. A CASE OF ANTI?INSULIN ANTIBODY/ANTI?INSULIN RECEPTOR ANTIBODY POSITIVE DIABETES IN WHICH COMBINATION THERAPY WITH INSULIN ASPART AND VOGLIBOSE WAS EFFECTIVE. T15/DIABETES/(ISSN:0021?437X)? THE 61ST ANNUAL MEETING OF THE JAPAN DIABETES SOC. 2018?61:S255",86.0,YR,E,M,Y,,,20180911.0,,MD,JP,JP,2018,Q3,Elderly
152313531,15231353,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, QW",,,N,,,,,1.5,MG,,/wk,2018,Q3,Hyperamylasaemia,,2018,Q3,1,I,20170905.0,20180724.0,20180802,20180802,EXP,,PHHY2018ES060171,SANDOZ,,53.0,YR,,M,Y,,,20180802.0,,OT,ES,ES,2018,Q3,Adult
152313531,15231353,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, QW",,,N,,,,,1.5,MG,,/wk,2018,Q3,Lipase increased,,2018,Q3,1,I,20170905.0,20180724.0,20180802,20180802,EXP,,PHHY2018ES060171,SANDOZ,,53.0,YR,,M,Y,,,20180802.0,,OT,ES,ES,2018,Q3,Adult
152389641,15238964,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, WEEKLY (1/W)",,,U,U, C942111,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Abdominal pain,,2018,Q3,1,I,201805.0,20180730.0,20180803,20180803,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201808000460,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20180803.0,,CN,GR,GR,2018,Q3,Adult
152389641,15238964,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, WEEKLY (1/W)",,,U,U, C942111,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Constipation,,2018,Q3,1,I,201805.0,20180730.0,20180803,20180803,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201808000460,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20180803.0,,CN,GR,GR,2018,Q3,Adult
152389641,15238964,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, WEEKLY (1/W)",,,U,U, C942111,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Syncope,,2018,Q3,1,I,201805.0,20180730.0,20180803,20180803,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201808000460,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20180803.0,,CN,GR,GR,2018,Q3,Adult
152543202,15254320,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, C884223C,,,0.75,MG,INJECTION,/wk,2018,Q3,Dyspepsia,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152543202,15254320,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, C884223C,,,0.75,MG,INJECTION,/wk,2018,Q3,Gastrooesophageal reflux disease,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152543202,15254320,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, C884223C,,,0.75,MG,INJECTION,/wk,2018,Q3,Malaise,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152543202,15254320,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, C884223C,,,0.75,MG,INJECTION,/wk,2018,Q3,Somnolence,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152543202,15254320,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, C884223C,,,0.75,MG,INJECTION,/wk,2018,Q3,Vomiting,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152543202,15254320,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,,0.75,MG,INJECTION,/wk,2018,Q3,Dyspepsia,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152543202,15254320,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,,0.75,MG,INJECTION,/wk,2018,Q3,Gastrooesophageal reflux disease,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152543202,15254320,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,,0.75,MG,INJECTION,/wk,2018,Q3,Malaise,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152543202,15254320,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,,0.75,MG,INJECTION,/wk,2018,Q3,Somnolence,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152543202,15254320,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,,0.75,MG,INJECTION,/wk,2018,Q3,Vomiting,,2018,Q3,2,F,201807.0,20180808.0,20180808,20180817,PER,,US-ELI_LILLY_AND_COMPANY-US201808002082,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180817.0,,CN,US,US,2018,Q3,Adult
152635361,15263536,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,Y,N,,,,,,,,2018,Q3,Abdominal pain,,2018,Q3,1,I,20180503.0,,20180720,20180720,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20180718.0,N,PH,US,US,2018,Q3,Elderly
152635981,15263598,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,Y,N,,,,,,,,2018,Q3,Diarrhoea,,2018,Q3,1,I,20180503.0,,20180720,20180720,DIR,,,FDA-CTU,,62.0,YR,,M,N,,,20180718.0,N,PH,US,US,2018,Q3,Adult
153153802,15315380,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q3,Acute kidney injury,,2018,Q3,2,F,20180807.0,20180910.0,20180824,20180920,EXP,,DE-JNJFOC-20180809993,PHARMACYCLICS,,65.0,YR,A,F,Y,120.0,KG,20180912.0,,MD,DE,DE,2018,Q3,Elderly
153153802,15315380,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q3,Hospitalisation,,2018,Q3,2,F,20180807.0,20180910.0,20180824,20180920,EXP,,DE-JNJFOC-20180809993,PHARMACYCLICS,,65.0,YR,A,F,Y,120.0,KG,20180912.0,,MD,DE,DE,2018,Q3,Elderly
153153802,15315380,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q3,Oedema,,2018,Q3,2,F,20180807.0,20180910.0,20180824,20180920,EXP,,DE-JNJFOC-20180809993,PHARMACYCLICS,,65.0,YR,A,F,Y,120.0,KG,20180912.0,,MD,DE,DE,2018,Q3,Elderly
153294321,15329432,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNKNOWN,,2018,Q3,Chest pain,,2018,Q3,1,I,20180109.0,20180109.0,20180829,20180829,PER,,US-JNJFOC-20180110400,JANSSEN,,38.0,YR,A,F,Y,130.64,KG,20180829.0,,OT,US,US,2018,Q3,Adult
153294321,15329432,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNKNOWN,,2018,Q3,Dyspnoea,,2018,Q3,1,I,20180109.0,20180109.0,20180829,20180829,PER,,US-JNJFOC-20180110400,JANSSEN,,38.0,YR,A,F,Y,130.64,KG,20180829.0,,OT,US,US,2018,Q3,Adult
153294321,15329432,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNKNOWN,,2018,Q3,Hypersensitivity,,2018,Q3,1,I,20180109.0,20180109.0,20180829,20180829,PER,,US-JNJFOC-20180110400,JANSSEN,,38.0,YR,A,F,Y,130.64,KG,20180829.0,,OT,US,US,2018,Q3,Adult
153294321,15329432,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNKNOWN,,2018,Q3,Pain in extremity,,2018,Q3,1,I,20180109.0,20180109.0,20180829,20180829,PER,,US-JNJFOC-20180110400,JANSSEN,,38.0,YR,A,F,Y,130.64,KG,20180829.0,,OT,US,US,2018,Q3,Adult
153516371,15351637,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2018,Q3,Pancreatitis acute,,2018,Q3,1,I,,20180831.0,20180905,20180905,EXP,,US-009507513-1809USA001027,MERCK,"WEST WA, UWAIFO GI. HEMOCHROMATOSIS AND CYSTIC FIBROSIS CARRIERS IDENTIFY RISK FOR GLP?1 AGONIST ASSOCIATED PANCREATITIS. DIABETES. 2018?67(SUPPL 1):A599",39.0,YR,,F,Y,,,20180905.0,,OT,US,US,2018,Q3,Adult
153678301,15367830,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,UNK,,,,,,,,,,,,2018,Q3,Gout,,2018,Q3,1,I,201808.0,20180831.0,20180910,20180910,PER,,US-TAKEDA-2018TUS026382,TAKEDA,,67.0,YR,,M,Y,,,20180910.0,,MD,US,US,2018,Q3,Elderly
153762891,15376289,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,D,,,,,1.0,DF,,QOW,2018,Q3,Atrioventricular block first degree,,2018,Q3,1,I,20180223.0,20180910.0,20180912,20180912,EXP,FR-AFSSAPS-PA20181098,FR-MYLANLABS-2018M1067131,MYLAN,,40.0,YR,,F,Y,97.0,KG,20180912.0,,MD,FR,FR,2018,Q3,Adult
153762891,15376289,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,D,,,,,1.0,DF,,QOW,2018,Q3,Coma,,2018,Q3,1,I,20180223.0,20180910.0,20180912,20180912,EXP,FR-AFSSAPS-PA20181098,FR-MYLANLABS-2018M1067131,MYLAN,,40.0,YR,,F,Y,97.0,KG,20180912.0,,MD,FR,FR,2018,Q3,Adult
153762891,15376289,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,D,,,,,1.0,DF,,QOW,2018,Q3,Hypovolaemic shock,,2018,Q3,1,I,20180223.0,20180910.0,20180912,20180912,EXP,FR-AFSSAPS-PA20181098,FR-MYLANLABS-2018M1067131,MYLAN,,40.0,YR,,F,Y,97.0,KG,20180912.0,,MD,FR,FR,2018,Q3,Adult
153762891,15376289,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,D,,,,,1.0,DF,,QOW,2018,Q3,Hypoxia,,2018,Q3,1,I,20180223.0,20180910.0,20180912,20180912,EXP,FR-AFSSAPS-PA20181098,FR-MYLANLABS-2018M1067131,MYLAN,,40.0,YR,,F,Y,97.0,KG,20180912.0,,MD,FR,FR,2018,Q3,Adult
153762891,15376289,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,D,,,,,1.0,DF,,QOW,2018,Q3,Miosis,,2018,Q3,1,I,20180223.0,20180910.0,20180912,20180912,EXP,FR-AFSSAPS-PA20181098,FR-MYLANLABS-2018M1067131,MYLAN,,40.0,YR,,F,Y,97.0,KG,20180912.0,,MD,FR,FR,2018,Q3,Adult
153762891,15376289,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Ophthalmic,"1 DF, Q3W",,,D,,,,,1.0,DF,,QOW,2018,Q3,Suicide attempt,,2018,Q3,1,I,20180223.0,20180910.0,20180912,20180912,EXP,FR-AFSSAPS-PA20181098,FR-MYLANLABS-2018M1067131,MYLAN,,40.0,YR,,F,Y,97.0,KG,20180912.0,,MD,FR,FR,2018,Q3,Adult
153789451,15378945,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, 1/WEEK",,,,,,,,,,,/wk,2018,Q3,Diarrhoea,,2018,Q3,1,I,201808.0,20180905.0,20180913,20180913,PER,,US-TAKEDA-2018TUS026707,TAKEDA,,70.0,YR,,F,Y,108.84,KG,20180913.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Decreased appetite,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Diarrhoea,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Dizziness,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Injection site erythema,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Injection site haemorrhage,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Nausea,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Retching,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Decreased appetite,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Diarrhoea,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Dizziness,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Injection site erythema,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Injection site haemorrhage,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Nausea,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154006632,15400663,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,,, C915210D,,,0.75,MG,INJECTION,,2018,Q3,Retching,,2018,Q3,2,F,20180917.0,20180924.0,20180919,20180928,PER,,US-ELI_LILLY_AND_COMPANY-US201809007866,ELI LILLY AND CO,,66.0,YR,,M,Y,,,20180928.0,,CN,US,US,2018,Q3,Elderly
154068871,15406887,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U,,,125469.0,,,,,2018,Q3,Blood test abnormal,,2018,Q3,1,I,,20180917.0,20180920,20180920,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201809006887,ELI LILLY AND CO,,49.0,YR,,F,Y,,,20180920.0,,CN,ES,ES,2018,Q3,Adult
154068871,15406887,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U,,,125469.0,,,,,2018,Q3,Discomfort,,2018,Q3,1,I,,20180917.0,20180920,20180920,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201809006887,ELI LILLY AND CO,,49.0,YR,,F,Y,,,20180920.0,,CN,ES,ES,2018,Q3,Adult
154068871,15406887,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,U,,,125469.0,,,,,2018,Q3,Vomiting,,2018,Q3,1,I,,20180917.0,20180920,20180920,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201809006887,ELI LILLY AND CO,,49.0,YR,,F,Y,,,20180920.0,,CN,ES,ES,2018,Q3,Adult
154135961,15413596,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, WEEKLY (1/W)",,,U,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Body mass index increased,,2018,Q3,1,I,201808.0,20180913.0,20180921,20180921,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201809006699,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180921.0,,CN,GR,GR,2018,Q3,Adult
154135961,15413596,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, WEEKLY (1/W)",,,U,U,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2018,Q3,Transaminases increased,,2018,Q3,1,I,201808.0,20180913.0,20180921,20180921,EXP,,GR-ELI_LILLY_AND_COMPANY-GR201809006699,ELI LILLY AND CO,,63.0,YR,,M,Y,,,20180921.0,,CN,GR,GR,2018,Q3,Adult
154298871,15429887,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,Y,U,,,,,,,,2018,Q3,Acute kidney injury,,2018,Q3,1,I,,20180917.0,20180926,20180926,EXP,,US-APOTEX-2018AP021116,APOTEX,"TAYLOR SR, MOODY MT. ACUTE KIDNEY INJURY OCCURRING IN A PATIENT INITIATED ON DULAGLUTIDE. DOI: 10.1177/8755122518782155. JOURNAL OF PHARMACY TECHNOLOGY. 2018?34 (5):231?232",63.0,YR,,F,Y,,,20180926.0,,PH,US,US,2018,Q3,Adult
154338451,15433845,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,Y,D,,,,,,,,2018,Q3,Anaphylactic shock,,2018,Q3,1,I,20180917.0,,20180921,20180921,DIR,,,FDA-CTU,,52.0,YR,,M,N,129.0,KG,20180921.0,N,PH,US,US,2018,Q3,Adult
154338451,15433845,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,Y,D,,,,,,,,2018,Q3,Angioedema,,2018,Q3,1,I,20180917.0,,20180921,20180921,DIR,,,FDA-CTU,,52.0,YR,,M,N,129.0,KG,20180921.0,N,PH,US,US,2018,Q3,Adult
154338451,15433845,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,Y,D,,,,,,,,2018,Q3,Therapy change,,2018,Q3,1,I,20180917.0,,20180921,20180921,DIR,,,FDA-CTU,,52.0,YR,,M,N,129.0,KG,20180921.0,N,PH,US,US,2018,Q3,Adult
144111843,14411184,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNSPECIFIED,,2018,Q4,Acute kidney injury,,2018,Q4,3,F,20160728.0,20181006.0,20180119,20181010,EXP,,US-JNJFOC-20171224039,JANSSEN,,38.0,YR,A,F,Y,124.29,KG,20181010.0,,CN,US,US,2018,Q4,Adult
144111843,14411184,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNSPECIFIED,,2018,Q4,Sepsis,,2018,Q4,3,F,20160728.0,20181006.0,20180119,20181010,EXP,,US-JNJFOC-20171224039,JANSSEN,,38.0,YR,A,F,Y,124.29,KG,20181010.0,,CN,US,US,2018,Q4,Adult
144111843,14411184,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,1.5,MG,UNSPECIFIED,,2018,Q4,Urinary tract infection,,2018,Q4,3,F,20160728.0,20181006.0,20180119,20181010,EXP,,US-JNJFOC-20171224039,JANSSEN,,38.0,YR,A,F,Y,124.29,KG,20181010.0,,CN,US,US,2018,Q4,Adult
146307204,14630720,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",7.0440001,MG,U,,,,,0.75,MG,SOLUTION FOR INJECTION,/wk,2018,Q4,Death,,2018,Q4,4,F,20170827.0,20181022.0,20180313,20181025,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201803003875,ELI LILLY AND CO,,74.0,YR,,F,Y,55.0,KG,20181025.0,,CN,JP,JP,2018,Q4,Elderly
152137133,15213713,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2018,Q4,Brain oedema,,2018,Q4,3,F,20180409.0,20181207.0,20180730,20181211,EXP,,JP-BEH-2018093214,CSL BEHRING,,77.0,YR,E,M,Y,62.6,KG,20181212.0,,MD,JP,JP,2018,Q4,Elderly
152137133,15213713,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2018,Q4,Cerebral infarction,,2018,Q4,3,F,20180409.0,20181207.0,20180730,20181211,EXP,,JP-BEH-2018093214,CSL BEHRING,,77.0,YR,E,M,Y,62.6,KG,20181212.0,,MD,JP,JP,2018,Q4,Elderly
152137133,15213713,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2018,Q4,Embolic stroke,,2018,Q4,3,F,20180409.0,20181207.0,20180730,20181211,EXP,,JP-BEH-2018093214,CSL BEHRING,,77.0,YR,E,M,Y,62.6,KG,20181212.0,,MD,JP,JP,2018,Q4,Elderly
152137133,15213713,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2018,Q4,Intracardiac thrombus,,2018,Q4,3,F,20180409.0,20181207.0,20180730,20181211,EXP,,JP-BEH-2018093214,CSL BEHRING,,77.0,YR,E,M,Y,62.6,KG,20181212.0,,MD,JP,JP,2018,Q4,Elderly
152137133,15213713,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2018,Q4,Pneumonia,,2018,Q4,3,F,20180409.0,20181207.0,20180730,20181211,EXP,,JP-BEH-2018093214,CSL BEHRING,,77.0,YR,E,M,Y,62.6,KG,20181212.0,,MD,JP,JP,2018,Q4,Elderly
153153803,15315380,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q4,Acute kidney injury,,2018,Q4,3,F,20180807.0,20181002.0,20180824,20181011,EXP,,DE-JNJFOC-20180809993,PHARMACYCLICS,,65.0,YR,A,F,Y,120.0,KG,20181011.0,,MD,DE,DE,2018,Q4,Elderly
153153803,15315380,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q4,Hypercalcaemia,,2018,Q4,3,F,20180807.0,20181002.0,20180824,20181011,EXP,,DE-JNJFOC-20180809993,PHARMACYCLICS,,65.0,YR,A,F,Y,120.0,KG,20181011.0,,MD,DE,DE,2018,Q4,Elderly
153153803,15315380,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q4,Oedema,,2018,Q4,3,F,20180807.0,20181002.0,20180824,20181011,EXP,,DE-JNJFOC-20180809993,PHARMACYCLICS,,65.0,YR,A,F,Y,120.0,KG,20181011.0,,MD,DE,DE,2018,Q4,Elderly
153153803,15315380,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q4,Renal failure,,2018,Q4,3,F,20180807.0,20181002.0,20180824,20181011,EXP,,DE-JNJFOC-20180809993,PHARMACYCLICS,,65.0,YR,A,F,Y,120.0,KG,20181011.0,,MD,DE,DE,2018,Q4,Elderly
154571181,15457118,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",2.625,MG,,,,,125469.0,1.5,MG,,/wk,2018,Q4,Enteritis,,2018,Q4,1,I,20180920.0,20180926.0,20181002,20181002,EXP,IT-MINISAL02-500842,IT-ELI_LILLY_AND_COMPANY-IT201809012789,ELI LILLY AND CO,,56.0,YR,,M,Y,95.0,KG,20181002.0,,CN,IT,IT,2018,Q4,Adult
154601561,15460156,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q4,Fournier's gangrene,,2018,Q4,1,I,20180822.0,,20181001,20181001,DIR,,,FDA-CTU,,65.0,YR,,M,N,102.5,KG,20181001.0,N,PH,US,US,2018,Q4,Elderly
154601561,15460156,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q4,Impaired quality of life,,2018,Q4,1,I,20180822.0,,20181001,20181001,DIR,,,FDA-CTU,,65.0,YR,,M,N,102.5,KG,20181001.0,N,PH,US,US,2018,Q4,Elderly
154918711,15491871,1,PS,DULAGLUTIDE 0.75 MG/0.5 ML,DULAGLUTIDE,1,Subcutaneous,,,,N,D,,,,0.75,MG,,QW,2018,Q4,Pancreatitis necrotising,,2018,Q4,1,I,20180917.0,,20181004,20181004,DIR,,,FDA-CTU,,72.0,YR,,M,N,93.2,KG,20180926.0,N,PH,US,US,2018,Q4,Elderly
154960511,15496051,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20170101.0,20181008.0,20181012,20181012,EXP,,PHHY2018FR122372,SANDOZ,,69.0,YR,,F,Y,85.0,KG,20181012.0,,OT,FR,FR,2018,Q4,Elderly
154960511,15496051,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2018,Q4,Hypotension,,2018,Q4,1,I,20170101.0,20181008.0,20181012,20181012,EXP,,PHHY2018FR122372,SANDOZ,,69.0,YR,,F,Y,85.0,KG,20181012.0,,OT,FR,FR,2018,Q4,Elderly
154982311,15498231,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20170101.0,20181005.0,20181015,20181015,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-093843,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,85.0,KG,20181015.0,,MD,FR,FR,2018,Q4,Elderly
154982311,15498231,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Hypotension,,2018,Q4,1,I,20170101.0,20181005.0,20181015,20181015,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-093843,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,85.0,KG,20181015.0,,MD,FR,FR,2018,Q4,Elderly
155007201,15500720,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION,/wk,2018,Q4,Cardiac failure acute,,2018,Q4,1,I,20170912.0,20181003.0,20181015,20181015,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201810002553,ELI LILLY AND CO,,68.0,YR,,M,Y,81.0,KG,20181015.0,,MD,JP,JP,2018,Q4,Elderly
155007201,15500720,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION,/wk,2018,Q4,Cholecystitis acute,,2018,Q4,1,I,20170912.0,20181003.0,20181015,20181015,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201810002553,ELI LILLY AND CO,,68.0,YR,,M,Y,81.0,KG,20181015.0,,MD,JP,JP,2018,Q4,Elderly
155007201,15500720,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION,/wk,2018,Q4,Myocardial ischaemia,,2018,Q4,1,I,20170912.0,20181003.0,20181015,20181015,EXP,,JP-ELI_LILLY_AND_COMPANY-JP201810002553,ELI LILLY AND CO,,68.0,YR,,M,Y,81.0,KG,20181015.0,,MD,JP,JP,2018,Q4,Elderly
155012381,15501238,9,C,DULAGLUTIDE ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Unknown,,,,,,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20170101.0,20181007.0,20181015,20181015,EXP,FR-AFSSAPS-AM20181340,FR-BAUSCH-BL-2018-027851,BAUSCH AND LOMB,,69.0,YR,,F,Y,85.0,KG,20181015.0,,MD,FR,FR,2018,Q4,Elderly
155012381,15501238,9,C,DULAGLUTIDE ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Unknown,,,,,,,,,,,,,2018,Q4,Hypotension,,2018,Q4,1,I,20170101.0,20181007.0,20181015,20181015,EXP,FR-AFSSAPS-AM20181340,FR-BAUSCH-BL-2018-027851,BAUSCH AND LOMB,,69.0,YR,,F,Y,85.0,KG,20181015.0,,MD,FR,FR,2018,Q4,Elderly
155235101,15523510,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20170101.0,20181004.0,20181018,20181018,EXP,FR-AFSSAPS-AM20181340,FR-ZYDUS-029146,ZYDUS PHARM,,69.0,YR,,F,Y,85.0,KG,20181018.0,,MD,FR,FR,2018,Q4,Elderly
155235101,15523510,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Hypotension,,2018,Q4,1,I,20170101.0,20181004.0,20181018,20181018,EXP,FR-AFSSAPS-AM20181340,FR-ZYDUS-029146,ZYDUS PHARM,,69.0,YR,,F,Y,85.0,KG,20181018.0,,MD,FR,FR,2018,Q4,Elderly
155252241,15525224,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,125469.0,,,,,2018,Q4,Jaundice,,2018,Q4,1,I,20171229.0,20181011.0,20181019,20181019,EXP,NL-LRB-00301042,NL-ELI_LILLY_AND_COMPANY-NL201810006270,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20181019.0,,CN,NL,NL,2018,Q4,Elderly
155252241,15525224,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,125469.0,,,,,2018,Q4,Nausea,,2018,Q4,1,I,20171229.0,20181011.0,20181019,20181019,EXP,NL-LRB-00301042,NL-ELI_LILLY_AND_COMPANY-NL201810006270,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20181019.0,,CN,NL,NL,2018,Q4,Elderly
155252241,15525224,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,U,,,125469.0,,,,,2018,Q4,Vomiting,,2018,Q4,1,I,20171229.0,20181011.0,20181019,20181019,EXP,NL-LRB-00301042,NL-ELI_LILLY_AND_COMPANY-NL201810006270,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20181019.0,,CN,NL,NL,2018,Q4,Elderly
155314271,15531427,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,, UNK,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20170101.0,20181005.0,20181019,20181019,EXP,,FR-AUROBINDO-AUR-APL-2018-050877,AUROBINDO,,69.0,YR,,F,Y,85.0,KG,20181019.0,,MD,FR,FR,2018,Q4,Elderly
155314271,15531427,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,, UNK,,,,,,,2018,Q4,Hypotension,,2018,Q4,1,I,20170101.0,20181005.0,20181019,20181019,EXP,,FR-AUROBINDO-AUR-APL-2018-050877,AUROBINDO,,69.0,YR,,F,Y,85.0,KG,20181019.0,,MD,FR,FR,2018,Q4,Elderly
155381801,15538180,9,C,DULAGLUTIDE ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,,UNK,,,,,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20170101.0,20181015.0,20181022,20181022,EXP,FR-AFSSAPS-AM20181340,FR-PFIZER INC-2018420341,PFIZER,,69.0,YR,,F,Y,85.0,KG,20181022.0,,MD,FR,FR,2018,Q4,Elderly
155381801,15538180,9,C,DULAGLUTIDE ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,,UNK,,,,,,,,,,,,2018,Q4,Hypotension,,2018,Q4,1,I,20170101.0,20181015.0,20181022,20181022,EXP,FR-AFSSAPS-AM20181340,FR-PFIZER INC-2018420341,PFIZER,,69.0,YR,,F,Y,85.0,KG,20181022.0,,MD,FR,FR,2018,Q4,Elderly
155413801,15541380,9,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Unknown,,,,,,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20170101.0,20181022.0,20181023,20181023,EXP,FR-AFSSAPS-AM20181340,FR-TEVA-2018-FR-967741,TEVA,,69.0,YR,,F,Y,85.0,KG,20181023.0,,MD,FR,FR,2018,Q4,Elderly
155413801,15541380,9,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Unknown,,,,,,,,,,,,,2018,Q4,Hypotension,,2018,Q4,1,I,20170101.0,20181022.0,20181023,20181023,EXP,FR-AFSSAPS-AM20181340,FR-TEVA-2018-FR-967741,TEVA,,69.0,YR,,F,Y,85.0,KG,20181023.0,,MD,FR,FR,2018,Q4,Elderly
155506391,15550639,9,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Unknown,(),,,U,U,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20170101.0,20181011.0,20181025,20181025,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-189091,RANBAXY,,69.0,YR,,F,Y,85.0,KG,20181025.0,,OT,GB,FR,2018,Q4,Elderly
155506391,15550639,9,C,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,2,Unknown,(),,,U,U,,,,,,,,2018,Q4,Hypotension,,2018,Q4,1,I,20170101.0,20181011.0,20181025,20181025,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-189091,RANBAXY,,69.0,YR,,F,Y,85.0,KG,20181025.0,,OT,GB,FR,2018,Q4,Elderly
155879861,15587986,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",6.0,MG,N,U,,,125469.0,1.5,MG,,/wk,2018,Q4,Colitis,,2018,Q4,1,I,20181015.0,20181026.0,20181105,20181105,EXP,GB-MHRA-EYC 00187931,GB-ELI_LILLY_AND_COMPANY-GB201810013731,ELI LILLY AND CO,,80.0,YR,,F,Y,,,20181105.0,,CN,GB,GB,2018,Q4,Elderly
155879861,15587986,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",6.0,MG,N,U,,,125469.0,1.5,MG,,/wk,2018,Q4,Diarrhoea,,2018,Q4,1,I,20181015.0,20181026.0,20181105,20181105,EXP,GB-MHRA-EYC 00187931,GB-ELI_LILLY_AND_COMPANY-GB201810013731,ELI LILLY AND CO,,80.0,YR,,F,Y,,,20181105.0,,CN,GB,GB,2018,Q4,Elderly
155879861,15587986,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",6.0,MG,N,U,,,125469.0,1.5,MG,,/wk,2018,Q4,Gastroenteritis,,2018,Q4,1,I,20181015.0,20181026.0,20181105,20181105,EXP,GB-MHRA-EYC 00187931,GB-ELI_LILLY_AND_COMPANY-GB201810013731,ELI LILLY AND CO,,80.0,YR,,F,Y,,,20181105.0,,CN,GB,GB,2018,Q4,Elderly
155879861,15587986,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",6.0,MG,N,U,,,125469.0,1.5,MG,,/wk,2018,Q4,Nausea,,2018,Q4,1,I,20181015.0,20181026.0,20181105,20181105,EXP,GB-MHRA-EYC 00187931,GB-ELI_LILLY_AND_COMPANY-GB201810013731,ELI LILLY AND CO,,80.0,YR,,F,Y,,,20181105.0,,CN,GB,GB,2018,Q4,Elderly
155879861,15587986,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",6.0,MG,N,U,,,125469.0,1.5,MG,,/wk,2018,Q4,Rectal haemorrhage,,2018,Q4,1,I,20181015.0,20181026.0,20181105,20181105,EXP,GB-MHRA-EYC 00187931,GB-ELI_LILLY_AND_COMPANY-GB201810013731,ELI LILLY AND CO,,80.0,YR,,F,Y,,,20181105.0,,CN,GB,GB,2018,Q4,Elderly
155879861,15587986,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",6.0,MG,N,U,,,125469.0,1.5,MG,,/wk,2018,Q4,Vomiting,,2018,Q4,1,I,20181015.0,20181026.0,20181105,20181105,EXP,GB-MHRA-EYC 00187931,GB-ELI_LILLY_AND_COMPANY-GB201810013731,ELI LILLY AND CO,,80.0,YR,,F,Y,,,20181105.0,,CN,GB,GB,2018,Q4,Elderly
155909181,15590918,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,Y,U,,,125469.0,,,,,2018,Q4,Pyoderma gangrenosum,,2018,Q4,1,I,201802.0,20181105.0,20181107,20181107,EXP,,US-ELI_LILLY_AND_COMPANY-US201811001619,ELI LILLY AND CO,"HAMANN C.R., CHUNG C., KAFFENBERGER B.H..PYODERMA GANGRENOSUM ASSOCIATED WITH DULAGLUTIDE THERAPY.INTERNATIONAL JOURNAL OF DERMATOLOGY. 2018;:.",55.0,YR,,F,Y,,,20181107.0,,MD,US,US,2018,Q4,Adult
155996951,15599695,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20180730.0,20181101.0,20181108,20181108,EXP,FR-AFSSAPS-AM20181484,FR-SEATTLE GENETICS-2018SGN02865,SEATTLE GENETICS,,67.0,YR,,M,Y,104.0,KG,20181108.0,,OT,FR,FR,2018,Q4,Elderly
155996951,15599695,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2018,Q4,Hyperthermia,,2018,Q4,1,I,20180730.0,20181101.0,20181108,20181108,EXP,FR-AFSSAPS-AM20181484,FR-SEATTLE GENETICS-2018SGN02865,SEATTLE GENETICS,,67.0,YR,,M,Y,104.0,KG,20181108.0,,OT,FR,FR,2018,Q4,Elderly
155996951,15599695,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2018,Q4,Malaise,,2018,Q4,1,I,20180730.0,20181101.0,20181108,20181108,EXP,FR-AFSSAPS-AM20181484,FR-SEATTLE GENETICS-2018SGN02865,SEATTLE GENETICS,,67.0,YR,,M,Y,104.0,KG,20181108.0,,OT,FR,FR,2018,Q4,Elderly
156094601,15609460,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, QW",,,N,, UNKNOWN,,,1.5,MG,,/wk,2018,Q4,Hyperamylasaemia,,2018,Q4,1,I,20170905.0,20181105.0,20181112,20181112,EXP,ES-AEMPS-362747,ES-MYLANLABS-2018M1084959,MYLAN,,53.0,YR,,M,Y,,,20181108.0,,MD,ES,ES,2018,Q4,Adult
156094601,15609460,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, QW",,,N,, UNKNOWN,,,1.5,MG,,/wk,2018,Q4,Lipase increased,,2018,Q4,1,I,20170905.0,20181105.0,20181112,20181112,EXP,ES-AEMPS-362747,ES-MYLANLABS-2018M1084959,MYLAN,,53.0,YR,,M,Y,,,20181108.0,,MD,ES,ES,2018,Q4,Adult
156242031,15624203,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, Q.WK. (1.5 MG, Q.WK.)",,,N,U,,,,1.5,MG,,/wk,2018,Q4,Hyperamylasaemia,,2018,Q4,1,I,20170905.0,20181106.0,20181116,20181116,EXP,ES-AEMPS-362747,ES-APOTEX-2018AP024629,APOTEX,,53.0,YR,,M,Y,,,20181116.0,,CN,ES,ES,2018,Q4,Adult
156242031,15624203,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, Q.WK. (1.5 MG, Q.WK.)",,,N,U,,,,1.5,MG,,/wk,2018,Q4,Lipase increased,,2018,Q4,1,I,20170905.0,20181106.0,20181116,20181116,EXP,ES-AEMPS-362747,ES-APOTEX-2018AP024629,APOTEX,,53.0,YR,,M,Y,,,20181116.0,,CN,ES,ES,2018,Q4,Adult
156285641,15628564,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,DAILY DOSE: 1.5 MG MILLGRAM(S) EVERY WEEKS,,,,,,,,1.5,MG,,/wk,2018,Q4,Coma,,2018,Q4,1,I,20181018.0,20181114.0,20181116,20181116,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-003735",BOEHRINGER INGELHEIM,,22.0,YR,,F,Y,185.0,KG,20181116.0,,MD,DE,DE,2018,Q4,Youth
156285641,15628564,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,DAILY DOSE: 1.5 MG MILLGRAM(S) EVERY WEEKS,,,,,,,,1.5,MG,,/wk,2018,Q4,Ketoacidosis,,2018,Q4,1,I,20181018.0,20181114.0,20181116,20181116,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-003735",BOEHRINGER INGELHEIM,,22.0,YR,,F,Y,185.0,KG,20181116.0,,MD,DE,DE,2018,Q4,Youth
156293993,15629399,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q4,Anaphylactic shock,,2018,Q4,3,F,20181031.0,20181127.0,20181117,20181129,EXP,,US-ROCHE-2215904,ROCHE,,50.0,YR,,F,Y,,,20181129.0,,MD,US,US,2018,Q4,Adult
156799802,15679980,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q4,Interstitial lung disease,,2018,Q4,2,F,,20181126.0,20181203,20181204,EXP,,JP-009507513-1812JPN000196,MERCK,SAKURAGI T ET AL. A CASE OF DRUG-INDUCED INTERSTITIAL PNEUMONIA DEVELOPED AFTER INTRODUCTION OF DULAGLUTIDE IN AN ELDERLY PATIENT WITH TYPE 2 DIABETES MELLITUS. THE 56TH CHUGOKU SHIKOKU REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY. 2018;1-D-26,84.0,YR,,M,Y,,,20181204.0,,OT,JP,JP,2018,Q4,Elderly
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Dysphagia,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Dyspnoea,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Erythema,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Hepatitis,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Mouth ulceration,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Oral pain,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Oral pruritus,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Pneumonitis,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Pseudomonas infection,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Rash vesicular,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Seizure,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Stevens-Johnson syndrome,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
156829751,15682975,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2018,Q4,Syncope,,2018,Q4,1,I,20180928.0,20181128.0,20181203,20181203,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113194,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,100.0,KG,20181203.0,,OT,GB,GB,2018,Q4,Adult
157042871,15704287,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20180908.0,,20181210,20181210,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20181210.0,N,,US,US,2018,Q4,Elderly
157042871,15704287,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20180908.0,,20181210,20181210,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20181210.0,N,,US,US,2018,Q4,Elderly
157158981,15715898,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,,/wk,2018,Q4,Ketoacidosis,,2018,Q4,1,I,,20181210.0,20181212,20181212,EXP,DE-BFARM-18016115,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-003945",BOEHRINGER INGELHEIM,,59.0,YR,,F,Y,,,20181213.0,,MD,DE,DE,2018,Q4,Adult
157158981,15715898,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,,/wk,2018,Q4,Ketonuria,,2018,Q4,1,I,,20181210.0,20181212,20181212,EXP,DE-BFARM-18016115,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-003945",BOEHRINGER INGELHEIM,,59.0,YR,,F,Y,,,20181213.0,,MD,DE,DE,2018,Q4,Adult
157288462,15728846,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QWK",,,,,,,,0.75,MG,INJECTION,/wk,2018,Q4,Cholangitis,,2018,Q4,2,F,20181205.0,20181214.0,20181217,20181227,EXP,,JP-JT-EVA201803874KERYXP-001,KERYX BIOPHARMACEUTICALS,,70.0,YR,,M,Y,78.0,KG,20181227.0,,MD,JP,JP,2018,Q4,Elderly
157349651,15734965,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Parenteral,"1.5 MG, WEEKLY (1/W)",0.214,MG,Y,, N/A,,125469.0,1.5,MG,,/wk,2018,Q4,Ageusia,,2018,Q4,1,I,20180808.0,20181212.0,20181218,20181218,EXP,GB-MHRA-EYC 00190862,GB-ELI_LILLY_AND_COMPANY-GB201812006101,ELI LILLY AND CO,,60.0,YR,,F,Y,62.0,KG,20181218.0,,CN,GB,GB,2018,Q4,Adult
157349651,15734965,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Parenteral,"1.5 MG, WEEKLY (1/W)",0.214,MG,Y,, N/A,,125469.0,1.5,MG,,/wk,2018,Q4,Asthenia,,2018,Q4,1,I,20180808.0,20181212.0,20181218,20181218,EXP,GB-MHRA-EYC 00190862,GB-ELI_LILLY_AND_COMPANY-GB201812006101,ELI LILLY AND CO,,60.0,YR,,F,Y,62.0,KG,20181218.0,,CN,GB,GB,2018,Q4,Adult
157349651,15734965,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Parenteral,"1.5 MG, WEEKLY (1/W)",0.214,MG,Y,, N/A,,125469.0,1.5,MG,,/wk,2018,Q4,Dizziness,,2018,Q4,1,I,20180808.0,20181212.0,20181218,20181218,EXP,GB-MHRA-EYC 00190862,GB-ELI_LILLY_AND_COMPANY-GB201812006101,ELI LILLY AND CO,,60.0,YR,,F,Y,62.0,KG,20181218.0,,CN,GB,GB,2018,Q4,Adult
157349651,15734965,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Parenteral,"1.5 MG, WEEKLY (1/W)",0.214,MG,Y,, N/A,,125469.0,1.5,MG,,/wk,2018,Q4,Dry mouth,,2018,Q4,1,I,20180808.0,20181212.0,20181218,20181218,EXP,GB-MHRA-EYC 00190862,GB-ELI_LILLY_AND_COMPANY-GB201812006101,ELI LILLY AND CO,,60.0,YR,,F,Y,62.0,KG,20181218.0,,CN,GB,GB,2018,Q4,Adult
157349651,15734965,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Parenteral,"1.5 MG, WEEKLY (1/W)",0.214,MG,Y,, N/A,,125469.0,1.5,MG,,/wk,2018,Q4,Eructation,,2018,Q4,1,I,20180808.0,20181212.0,20181218,20181218,EXP,GB-MHRA-EYC 00190862,GB-ELI_LILLY_AND_COMPANY-GB201812006101,ELI LILLY AND CO,,60.0,YR,,F,Y,62.0,KG,20181218.0,,CN,GB,GB,2018,Q4,Adult
157349651,15734965,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Parenteral,"1.5 MG, WEEKLY (1/W)",0.214,MG,Y,, N/A,,125469.0,1.5,MG,,/wk,2018,Q4,Heart rate increased,,2018,Q4,1,I,20180808.0,20181212.0,20181218,20181218,EXP,GB-MHRA-EYC 00190862,GB-ELI_LILLY_AND_COMPANY-GB201812006101,ELI LILLY AND CO,,60.0,YR,,F,Y,62.0,KG,20181218.0,,CN,GB,GB,2018,Q4,Adult
157349651,15734965,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Parenteral,"1.5 MG, WEEKLY (1/W)",0.214,MG,Y,, N/A,,125469.0,1.5,MG,,/wk,2018,Q4,Nausea,,2018,Q4,1,I,20180808.0,20181212.0,20181218,20181218,EXP,GB-MHRA-EYC 00190862,GB-ELI_LILLY_AND_COMPANY-GB201812006101,ELI LILLY AND CO,,60.0,YR,,F,Y,62.0,KG,20181218.0,,CN,GB,GB,2018,Q4,Adult
157349651,15734965,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Parenteral,"1.5 MG, WEEKLY (1/W)",0.214,MG,Y,, N/A,,125469.0,1.5,MG,,/wk,2018,Q4,Off label use,,2018,Q4,1,I,20180808.0,20181212.0,20181218,20181218,EXP,GB-MHRA-EYC 00190862,GB-ELI_LILLY_AND_COMPANY-GB201812006101,ELI LILLY AND CO,,60.0,YR,,F,Y,62.0,KG,20181218.0,,CN,GB,GB,2018,Q4,Adult
157349651,15734965,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Parenteral,"1.5 MG, WEEKLY (1/W)",0.214,MG,Y,, N/A,,125469.0,1.5,MG,,/wk,2018,Q4,Vomiting,,2018,Q4,1,I,20180808.0,20181212.0,20181218,20181218,EXP,GB-MHRA-EYC 00190862,GB-ELI_LILLY_AND_COMPANY-GB201812006101,ELI LILLY AND CO,,60.0,YR,,F,Y,62.0,KG,20181218.0,,CN,GB,GB,2018,Q4,Adult
